Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Reposting; I missed Swim’s add of 45k Common since 8-30-17, per today’s Ronin/SW PR and the 14A followup.
= = = = = = = = = =RONIN/SWInvest 13D DETAIL TRANS:
10-10-17/14A(Ronin’s PR) COMMON ONLY: http://tinyurl.com/ybvkjd3e
This Ronin/SWIM PR has a section at the bottom giving updated ownership figures. It shows that SWIM added 45,000sh. of Common since the last 14A dated 8-29-17, taking SWIM from 655,000 to 700,000. This results in Ronin/SW Group total beneficial ownership moving from 3,979,699 to 4,024,699 (8.9% of 45,096,081 common outstanding as of 8-25-17).
Was waiting on the next PPHM/Ronin/Shareholders to update, but I think it's time to add SITC'17 regardless...
See:
Nov8-12 2017: “(SITC) Society for Immunotherapy of Cancer 32nd Annual Meeting”, Natl-Harbor MD
http://investorshub.advfn.com/boards/manage_msg.asp?message_id=134756056
KNOWN UPCOMING:
Sep25-28/Avid(booth #918): Informa’s BPI’17: BioProcess Intl. Conf. & Exhibition, Boston https://lifesciences.knect365.com/bioprocessinternational
Oct2/NCI Scientist Gregoire Altan-Bonnet(MSKCC ties), AACR’s Tumor Immunotherapy Conf., Boston http://tinyurl.com/y74v76go
...“Long-Lived Disruption of Inflammation Stems from the Catch-and-Release of Cytokines Mediated by Surface Phosphatidylserine in Tumors”
Oct6/Avid(booth): LakePharma Protein Eng. Symposium, So.SanFran http://tinyurl.com/ya6yvetk
~Oct12(??based on 2016): Peregrine's Annual Shareholder’s Meeting (2016 attendee reports: http://tinyurl.com/jx7ouay )
Nov8-12: 32th Annual SITC’17, Natl-Harbor MD http://tinyurl.com/ybfm75wj
...1. PPHM-PrecisionMed: “Results of Epigenetic-Based Quantitative PCR Assisted Immune Cell Counting Analysis in Bavi SUNRISE Trial Subgroup”
...2. MSKCC-PPHM: “PS-Targeting In Combo w/Rad+Immune Checkpoint Blockade Promotes Anti-Tumor Activity in Mouse B16 Melanoma”
Dec11-15/Avid Booth #311: KNect365’s Antibody Eng. & Therapeutics Conf., SanDiego https://lifesciences.knect365.com/antibody-engineering-therapeutics
~Dec11: FY'18Q2 (qe 10-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Jan18-22 2018: Phacilitate’s Immunotherapy World Forum, Miami http://www.immunotherapyforum.com
...Jan18 12:30-12:45, Joe Shan(VP/Reg+Clin): “Turning up the Heat: PS-Targeting Antibodies Modulate the Tumor Microenvironment & Enhance Checkpoint Blockade”
Re: Eastern/Dart 9-29-17 Form4: Maybe, but he’s been under 10% for a few months now, so how could that be what triggered it now?
Also, the box X’d says, “if no longer subject to Section 16.”, but then also says, “Form 4 or Form 5 obligations may continue.” Is that maybe a diff. between 5% and 10% requirements?
Finally, another strange thing about this “3. Date of Earliest Trans: 9/11/2017.”
The whole thing is weird (to ME)!
= = = = = = = = = = = = = = = = =
9-29-17 Form4 Eastern/Dart:
https://www.sec.gov/Archives/edgar/data/704562/000140840817000032/xslF345X03/ecl_pphmform4092017.xml
10-30-15: Kenneth Dart (Eastern Capital) acquires 9.5% (presently) stake (4,300,992sh.) in PPHM http://tinyurl.com/y95yskck
...3,777,183 COMMON – 8.4% of 45,096,081 common O/S at 8-25-17 (total beneficial=4,300,992 if Pref. conv. x1.19 to Common, 9.5%)
...440,000 PREFERRED – 26.7% of 1,647,760 preferred O/S at 1-31-17
…...9-29-17/Form4: http://tinyurl.com/y9oadloa ???
8-2016: One 5% Stockholder: Eastern Capital Limited (Kenneth Dart), Grand Cayman Islands
...from Form14A ASM Proxy http://tinyurl.com/ybu8nr7l
8-2016: “The info. set forth herein is based solely on a Schd. 13G/A filed 11-2-15 by Eastern Capital Ltd. The number of beneficial shares owned (30,106,945sh.) includes 3,666,667 shares of common stock that could be acquired upon conversion of the 440,000 shares of Series E Preferred Stock held by Eastern Capital.”
11-2-15/E.Cap 13G & Form3: http://tinyurl.com/pexs62e & http://tinyurl.com/ns2s9p6
Thx/PM: "This same joint PPHM+MSKCC TITLED poster was presented..."
Huts, Eastern(K.Dart)’s 3,777,183 COMMON (8.4%) matches what I posted in my latest “Large Ownership Summary(34.8%)” update, except that he also owns 440,000sh. of PREFERRED.
See: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=134685455
PS: I do wish you had posted the LINK to that info (as always).
#1: 10-30-15: Kenneth Dart (Eastern Capital) acquires 9.5% stake (4,300,992sh.) in PPHM http://tinyurl.com/y95yskck
...3,777,183 COMMON – 8.4% of 45,096,081 common O/S at 8-25-17 (total beneficial=4,300,992 if Pref. conv. x1.19 to Common, 9.5%)
...440,000 PREFERRED – 26.7% of 1,647,760 preferred O/S at 1-31-17
2nd SITC’17(Nov8-12) Title: Joint MSKCC(Wolchok Lab)+PPHM
Nov8-12 2017: “(SITC) Society for Immunotherapy of Cancer 32nd Annual Meeting”, Natl-Harbor MD
”The premier destination for scientific exchange, education, and networking in the Cancer Immunotherapy Field”
SITC = The Society for Immunotherapy of Cancer http://www.sitcancer.org
SITC 2017 Meeting: http://www.sitcancer.org/2017/home
Abstracts: http://www.sitcancer.org/2017/abstracts All abstracts submitted to the SITC 32nd Annual Meeting will be published in the Journal for ImmunoTherapy of Cancer (JITC), the official journal of SITC. Regular abstracts will be published on Tuesday, Nov. 7 and LBA's will be published on Dec. 7.
= = = = =So far:
1. “Results of Epigenetic-Based Quantitative PCR Assisted Immune Cell Counting Analysis in Bavituximab SUNRISE Trial Subgroup”
https://www.sitcancer.org/2017/abstracts/titles/biomarkers-immune-monitoring
Nikoletta L. Kallinteris 1, Thomas O. Kleen 2, Min Tang 1, Shen Yin 1, Tobi Guennel 3, Jennifer Lai 1, Victor Nowakowski 2, Steven Olek 2, Steve King 1, Joseph S. Shan 1
1 Peregrine Pharmaceuticals
2 Epiontis GmbH, Berlin, Germany
3 Precision Medicine, Frederick MD
2. “Phosphatidylserine Targeting Antibody In Combination With Tumor Radiation & Immune Checkpoint Blockade Promotes Anti-Tumor Activity in Mouse B16 Melanoma”
https://www.sitcancer.org/2017/abstracts/titles/combination-therapy
Sadna Budhu 1, Rachel Giese 1, Olivier De Henau 1, Roberta Zappasodi 1, Luis Felipe Campesato 1, Aditi Gupta 1, Christopher Barker 1, Bruce Freimark 2, Jedd D. Wolchok 1, Taha Merghoub 1
1 Memorial Sloan Kettering Cancer Center, NYC
2 Peregrine Pharmaceuticals, Inc.
...NOTE: This same joint PPHM+MSKCC poster was presented 11-11-16 at SITC’16 (http://tinyurl.com/js3fca4 ) and 4-2-17 at AACR’17 (http://tinyurl.com/lxlltd6 ).
= = = = = = = = = =
Peregrine began working w/Mem-Sloan-Kettering(Jedd Wolchok Lab) in Jul'15 (2 known studies a/o 4-2017: #1/Bavi+PD1+Rad, #2/Bavi+”ACT”) to investigate “Novel PS-Targeting Immunotherapy Combos”. See: http://tinyurl.com/lxlltd6
Known Upcoming Events, Large-Shareholders(35%), RONIN-PPHM HISTORY: updated 9-17-17 with PPHM’s 9-11-17 announcement that Roger J. Lias, 57, will become Avid’s President and join PPHM’s BOD eff. 9-25-17.
NOTE: RONIN/SWIM’s 8-29-17 PRELIM. Proxy Statement (14A) and PPHM’s 8-28-17 Amended 10-K were added previously – see below...
KNOWN UPCOMING:
Sep25-28/Avid Booth #918: Informa’s BPI’17: BioProcess Intl. Conf. & Exhibition, Boston https://lifesciences.knect365.com/bioprocessinternational
Oct2/NCI Scientist Gregoire Altan-Bonnet(MSKCC ties), AACR’s Tumor Immunotherapy Conf., Boston http://tinyurl.com/y74v76go
...“Long-Lived Disruption of Inflammation Stems from the Catch-and-Release of Cytokines Mediated by Surface Phosphatidylserine in Tumors”
~Oct12(??based on 2016): Peregrine's Annual Shareholder’s Meeting (2016 attendee reports: http://tinyurl.com/jx7ouay )
Dec11-15/Avid Booth #311: KNect365’s Antibody Eng. & Therapeutics Conf., SanDiego https://lifesciences.knect365.com/antibody-engineering-therapeutics
~Dec11: FY'18Q2 (qe 10-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Jan20-22 2018: Phacilitate’s Immunotherapy World Forum, Miami http://www.immunotherapyforum.com
...Jan18 12:30-12:45, Joe Shan(VP/Reg+Clin): “Turning up the Heat: PS-Targeting Antibodies Modulate the Tumor Microenvironment & Enhance Checkpoint Blockade”
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
7-20-17: Large Ownership Summary(34.8%), RONIN Letters/PPHM Comments
Large Ownership now ~15.8mm shares, 34.9% of 45,096,081 O/S at 9-6-17. (Ronin+SW/Stafford+White, Eastern Cap./K.Dart, Institutions incl. Tappan’s 8-14-17/13G)
#1: 10-30-15: Kenneth Dart (Eastern Capital) acquires 9.5% stake (4,300,992sh.) in PPHM http://tinyurl.com/y95yskck
...3,777,183 COMMON – 8.4% of 45,096,081 common O/S at 8-25-17 (total beneficial=4,300,992 if Pref. conv. x1.19 to Common, 9.5%)
...440,000 PREFERRED – 26.7% of 1,647,760 preferred O/S at 1-31-17
#2: 7-14-17/13D: Group Ronin Trading/SWInvest (John Stafford III+Stephen White) acquires 8.8% stake (3,979,699sh.) in PPHM http://tinyurl.com/y7ezqvm9
...3,828,391 COMMON – 8.5% of 45,096,081 common O/S at 8-25-17 (total beneficial=3,979,699 if Pref. conv. x1.19 to Common, 8.8%)
...127,099 PREFERRED – 7.7% of 1,647,760 preferred O/S at 1-31-17
NOTE: ALL historical common #’s adjusted for the 1:7 R/S eff. 7-10-17.
RONIN/SW 13D SUMMARY:
13D TransDates COMMON-CHG PREF-CHG ENDING-COMMON ENDING-PREF.
3-2-17 1/20/17-3/1/17 +2,947,425 +51,364 2,947,425 51,364 http://tinyurl.com/jr42u23
3-10-17 3/2/17-3/9/17 +433,509 +25,661 3,380,934 77,025 http://tinyurl.com/ydxra96u
4-17-17 3/28/17-4/10/17 0 +23,334 3,380,934 100,359 http://tinyurl.com/lanjddc
5-19-17 5/1/17-5/17/17 0 +23,140 3,380,934 123,499 http://tinyurl.com/mgnn92x
6-20-17 3/10/17-6/16/17 +378,170 0 3,759,105 123,499 http://tinyurl.com/y76q5rqu
6-29-17 6/21/17 +7,143 0 3,766,248 123,499 http://tinyurl.com/y9sp8bfv
7-14-17 6/29/17-7/7/17 +34,891 +3,600 3,801,139 127,099 http://tinyurl.com/ybra4s69
8-29-17 8/4/17-8/15/17 +27,252 0 3,828,391 127,099 http://tinyurl.com/yay55u3p (14A)
SPLITOUT 13D GROUP into Ronin(John Stafford III) and SW-Partners(Stephen White):
Ronin Trading (Stafford) 3,173,391 115,299
SW-Partners (White) 655,000 11,800
See Ronin/SWIM 13D’s Details Below.
- - - - - - - - - - - - - - -
Plus, INSTITUTIONS a/o 6-30-17: 7,476,857sh. = 16.6% <=incl. Tappan’s 8-14-17/13G,
...and KennedyCAP corrected 9,758,459=>1,394,066(Nasdaq R/S error)
...15,198,818 +(1,394,066-9,758,459) + (2,298,684-1,656,252) = 7,476,857
http://www.nasdaq.com/symbol/pphm/institutional-holdings
TOP7:
Tappan St. Partners 2,298,684 +1,384,380 <=per 8-14-17/13G(see below**)
Kennedy Capital Mgt. 1,394,066 +146,842
Vanguard Group 1,029,755 +146,791
Blackrock (Larry Fink) 806,022 -49,433
Renaissance Technologies 481,160 +41,487
Geode Capital Mgt. 225,679 +20,319
Bandera Partners 203,004 New
**8-14-17/13G: Tappan Street (Prasad Phatak) http://tinyurl.com/ybgqp9uq
2 Funds + P.Phatak’s personal shares:
...Partners LLC, Tappan St. Fund L.P. 1,540,000
...Tappan St. Partners Ideas Fund L.P. 691,577
...Prasad Phatak (Principle Owner) 67,107 Total TAPPAN: 2,298,684 (5.1%)
Note: Tappan Inst. Holdings a/o 3-31-17 was: 914,304, 1,656,252 at 6-30-17.
9-11-17 Qtly CC-Transcript, PR(Fin’s Q1FY18/qe7-31-17), Avid Revs History Table
=> Total Revs May06-Jul17: $258.3mm/Avid + $24.1mm/Govt + $2.4mm/Lic. = $284.9mm.
Cash at 7-31-17: $37.3mm (Op. Cash Burn for q/e 7-31-17 was $78k – see below).
As of Sept. 6, 2017, there were 45,096,081 shares outstanding. (10Q 7-31-17 iss. 9-11-17 http://tinyurl.com/ycbzp4zn )
...NOTE: PPHM shares were 1:7 Reverse Split eff. 7-10-17 (315mm/$.606=>45mm/$4.24) http://tinyurl.com/ycohqn6j
This large post has 4 sections:
I. 9-11-17 Q1/FY18 Qtly. Earnings Conf. Call TRANSCRIPT (q/e 7-31-17)
II. 9-11-17 PPHM Press Release: Q1/FY18 Earnings & Developments
III. A link to “O/S Shares & ATM Sales History – 2006-curr.” (http://tinyurl.com/ybjgm425 )
IV. Updated Table of Avid Revenues By Quarter (May’06-Current)
…Recall: Peregrine’s FY runs May-Apr, so FY’18 = May’17-Apr’18.
((( Orig. transcript from SeekingAlpha.com [http://tinyurl.com/yd3zp6gu ], with numerous corrections made. )))
Link to webcast replay: http://ir.peregrineinc.com/events.cfm => http://edge.media-server.com/m/p/h72967p8
FULL TRANSCRIPT… 9-11-17 FY’18/Q1 Earnings Conf. Call (q/e 7-31-17) (King/Lias/Lytle)
WELCOME & FWD-LOOKING STATEMENTS: Tim Brons, Vida Strategic Partners (IR) http://www.peregrineinc.com
CEO STEVE KING – OPENING COMMENTS:
Thanks to all of you who have dialed in and all of you who are participating via webcast today. I would actually like to start with a moment of silence in respect to those that died in the 9/11 terrorist attacks and for those that have been affected by the recent hurricanes.
Over the past year and a half, following the negative results from our Phase III SUNRISE trial, we have seen the company change from an R&D-focused business that has been running a contract dev. & mfg. organization, or CDMO, on the side to a CDMO business that has been running R&D on the side. I am very proud that we have been able to grow our CDMO business, Avid Bioservices, from an internal support operation to a full service CDMO that now manufactures bulk drug substance for products that are approved and marketed in over 18 countries by leading biopharma companies. The company was recently recognized as a leading CDMO by Life Science Leader and received multiple 2017 Contract Mfg. Leadership Awards for Quality, Reliability, Capabilities, Expertise, and Compatibility. Avid has an outstanding regulatory inspection history and state-of-the-art cGMP mfg. Facilities. This growth did not happen by accident. It is the result of the dedication, selflessness, and intense effort by the Avid and Peregrine employees that have been involved in the business, which has always been the secret of our success and will continue to be in the future.
We have two very different businesses, CDMO and R&D, within Peregrine with different investment and growth strategies and the two efforts need to be separated so that each has a better opportunity for success. From a business standpoint, we want to ensure the success of Avid which represents a relatively lower-risk business that can be grown over the coming years to create significant stockholder value. In the meantime, we also want to find the best strategic options for advancing the bavituximab and PS-Exosome diagnostic programs, which will require significant short-term investments, which by the very nature of R&D is relatively high risk and capital intensive.
The appointment of Dr. Roger Lias as president of Avid Bioservices [9-11-17: http://tinyurl.com/yd3eh3uv ] and his appointment to Peregrine's Board of Directors marks an important next step in this transition. Roger is a highly experienced executive with a long track record of success in the CDMO industry, and was an ideal candidate for the position. We have a successful commercial CDMO business, and we look forward to taking Avid to the next level under Roger's leadership. Naturally, job one will be a smooth transition to ensure we continue to support our existing clients, while simultaneously working to attract new clients as we look to grow the business on multiple fronts.
As we focus on the success of the CDMO business, we have been evaluating the best options for divesting our R&D assets. The goal being to find a partner that will make a significant short-term investment in the bavituximab program in order to validate the subset analysis from the Phase III SUNRISE trial and build on recent data from our collaborators. The subset analysis, which supports the combination of bavituximab with checkpoint inhibitors, is compelling but needs further clinical validation. This data, combined with findings from our collaborators at Memorial Sloan Kettering Cancer Center (MSKCC – See 4-14-17: http://tinyurl.com/lxlltd6 ) supporting combinations with cellular therapies including CAR-T and the ongoing trials from our partners at the National Comprehensive Cancer Network (NCCN), all as outlined in our earnings release, have bolstered our belief that our bavituximab program can be successfully advanced in the right hands. However, there is still much work to be done to realize this value. For this reason, we have concluded that in order to best position Peregrine’s R&D assets for successful development, they should be advanced by a partner with the appropriate expertise and ample resources to invest in the necessary clinical trials. To that end, we have been working diligently towards the transformation of the overall business to becoming a pure-play CDMO, while assessing the best strategic options for the R&D assets that would allow stockholders to directly see the future value from their continued developments. By partnering and eliminating future R&D expenditures, we believe we are best positioning Avid for future growth. Through reinvestment and expansion, we believe we will attract new customers and extend current contracts that will help position Avid as a leading U.S. CDMO. We are moving forward expeditiously with strategic discussions as we recognize the need to move quickly both from the R&D & CDMO standpoints. We hope to bring this process to completion over the coming months and will update you on our progress.
----------NCCN:
[NCCN Bavituximab Trials Announced 9-6-16 http://tinyurl.com/gutgwb5
...#1: Ph1/HepC-Related Hepatocellular(Liver) (Bavi+RAD+Bayer’s Nexavar=Sorafenib), MOFFITT CC (N=18)
. . . . . . .PI: Jessica Frakes, MD https://clinicaltrials.gov/ct2/show/NCT02989870 <=Recruiting 3-27-17
...#2: Ph2/Newly Diag. Glioblastoma (Bavi+RAD+Merck’s Temodar), MASS-GEN. & DANA FARBER (N=36)
. . . . . . .PI: Elizabeth Gerstner, MD https://clinicaltrials.gov/ct2/show/NCT0313991 <=Recruiting 6-16-17, 1stDose=9/7/17
...#3: Ph2/Progressive Squamous Head+Neck (Bavi+Merck’s Keytruda), JOHNS-HOPKINS(Sidney Kimmel CC)
. . . . . . .PI: Ranee Mehra, MD https://clinicaltrials.gov/ct2/show/XXXXX - See Dr. R.Mehra Jan'17/IFN-y Biomarker: http://tinyurl.com/h8gzkww
Now back to Avid. We have continued to see lots of activity on the CDMO front, including Q1 revs of $27mm. And while we are projecting a relatively flat revenue year, based on the decreased FY’18 forecasts from our 2 largest customers, we do believe this decrease will be temporary and expect that Avid will continue to thrive despite lower revenue from these 2 clients in the short term. There could still be a revenue upside this year as our new customers continue to move towards GMP mfg. and the potential to bring on even more new customers. In addition to our business dev. efforts, we have also continued to make critical investments in our CDMO facilities to ensure that we offer the most state-of-the-art systems. During the quarter, we installed 2 new 2,000L bioreactors in the Myford facility and we have already secured commitments for this capacity. Due to its modular design, there’s a potential to install addl. bioreactors in our Myford facility which will allow us to grow the business in the future. In addition, we continue to evaluate options to expand Avid’s offerings in order to meet even more needs for our existing & prospective clients. I would now like to turn the call over to Roger for a few words on his joining the company and future directions, and we will then turn the call over to Paul Lytle for a discussion of financial highlights for the qtr and for the remainder of the FY.
ROGER LIAS (President/Avid eff. 9-25-17):
...9-11-17/PR: Dr. Lias hired as Avid’s President (also to join BOD): http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=1039872
Thanks, Steve, and good afternoon, everyone. I’d first like to say that I’m absolutely delighted to be able to join the Avid Bioservices team at what is a very exciting time for the company. It’s clear that the broad biologics market remains robust and there is undoubtedly very strong demand for high-quality contract dev. & mfg. services to support the dev. and launch of a wide range of important therapeutic biological products. Based on my personal long experience in this field, stretching way back to the formative perhaps market-making years at Celltech Biologics, which is now Lonza, and at companies such as Diosynth, KBI BioPharma, Cytovance Biologics, and Eden Biodesign, I very strongly believe that the building blocks are mostly in place here at Avid to support growth & transition to a world-leading CDMO. I’ve had the opportunity to look at Avid recently both as a competitor over the years and even more recently as a consultant supporting a very well funded company on the East Coast that has selected, I’m pleased to say, Avid as its preferred mfg. for a very interesting and potentially lifesaving product that should move rapidly to commercialization. The decision-making process for this company was multifaceted. The quality and capabilities go without saying, and ultimately the decision to come to Avid came down to the employees, the people, the flexible and creative approach, and the ability to meet timelines. And it’s interesting that Avid beat out most major contract anufacturers to win this project, and I was certainly duly impressed. In many ways, Avid is in a very unusual position relative to its peer contract manufacturers based on the somewhat unorthodox way in which the company has evolved. An exemplary 12-year track record in releasing commercial batches is very unusual and coupled with almost 25 years of overall experience in biologics, process development, and manufacture, this represents a truly tremendous platform from which to grow the company.
There’s clearly work to be done, however. Over the shorter term, I believe we clearly need to diversify the client base and to continue to grow the order book and revenue backlog. I believe that as part of this effort, Avid’s market visibility & reach needs to be dramatically increased. The new Myford mfg. facility represents a tremendous opportunity and obviously needs to be filled as a priority, and I’m pleased to see progress in that direction already. I believe that Avid’s earlier stage process dev. and process sciences capabilities need to be strengthened, both in support of mfg. operations and to create a stronger pipeline of future mfg. projects and addl. revenue stream. Stepping back and taking the longer view, there’s clearly exciting opportunities for considerable growth, both organically and potentially via mergers and acquisitions. Clearly I believe the available Myford II expansion space provides opportunities to add additional commercial drug substance manufacturing to the type already installed, but we should also examine opportunities to potentially add earlier discovery services to feed the process development and subsequent mfg. pipeline and potentially latest stage drug product mfg. services that will fill and finish a product. I believe strongly that we also need to be ready to look beyond antibodies and recombinant proteins and to take advantage of growing market demand for newer classes of products such as viral vectors and vaccines. These support exciting new therapeutic advantages in gene, cellular and immunotherapies, antibody-drug conjugates, and bio multi-specific antibody products. Each of these has specific technical and operational challenges that will need to be carefully addressed, but the opportunities are significant and I believe the timing is very good. So in closing, I’m very much looking forward to getting started and I believe that the future looks very bright for the broad biologics market and for Avid Bioservices in particular. I’m very much looking forward to taking Avid to the next level and to reporting on progress during future calls. And with that, I’d hand over to Paul who will cover the quarterly results in more detail.
PAUL LYTLE (CFO): [7-31-17 10Q iss. 9-11-17: http://tinyurl.com/ycbzp4zn ]
I’ll now discuss our financial results for Q1/FY18, starting with revenue. As a backdrop, our revenue guidance for FY’18 is expected to be $50-55mm, of which we recognized $27mm during Q1. This included $10mm in revenue that shifted from Q4 of FY’17 to Q1 due to a customer requested shipping delay. This represents an increase in revenue of 383% vs. $5.6 million that we reported during the same prior year period. While we had an excellent quarter, we have also seen decreases in mfg. from our 2 largest customers. As a result, we saw revenue backlog decline to ~$33mm at the end of the current qtr. As we look ahead, adding new customers and diversifying our customer base will be extremely important to growing revenue. This is the key reason we have hired a President of Avid solely focused on our CDMO business and someone who is highly connected to the bio-mfg. industry. Let me shift gears now to discuss our gross margins on contract mfg.. During Q1, our gross margins declined to 24% mostly due to a higher percentage of revenue related to pass through charges, such as raw materials, that are recorded to revenue at cost plus a nominal mark-up. This is relatively standard for our industry. During Q1, 38% of our revenue was related to pass through charges vs. 20% in the same prior year qtr, thereby lowering the overall gross margin. In addition, we saw lower capacity utilization during the current qtr in addition to unavailable capacity while we installed and validated two 2,000 liter bioreactors which are now operational. This also impacted our gross margins for Q1 vs. the same prior year period. Now turning to R&D, we are continuing our commitment to reduce R&D spending. In FY17 [May’16-Apr’17], we reported a 52% decline in R&D expenses and we have continued this trend into Q1/FY18, achieving a 57% reduction in R&D expenses. Based on our plan to pursue strategic alternatives for our R&D assets, we expect R&D expenses to decline at least 50% overall this year, and it could be a greater percentage decline depending on the timing of any potential transaction around the R&D assets. In summary, the increase in mfg. Revenue, combined with a decrease in R&D spending, has translated into a reduction in our net loss by 89% to $1.2mm for Q1 vs. a net loss of $11mm for the same prior year period.
Q&A: [beg. 16:16]
1. George Zavoico – (FBR & Co.): http://www.fbr.com
GZ: ”Hi, everyone. Good afternoon. And Roger welcome to Peregrine. I have a question for you. The revenue & client customer base, it’s kind of choppy, kind of up & down as you’ve seen and as Peregrine has seen lately. What in your view do you see as the critical mass that you need in terms of customer base to sort of eliminate some of that choppiness in terms of number of customers and volumes? In other words, what’s your goal, what’s your objective to get to that point?”
Roger Lias: Yes, I think the key thing is to look – we’re very well positioned to given the track record and obviously the available capacity to potentially bring in later phase clients and to technology transfer in programs that can go straight into commercial mfg., and clearly that’s a major objective. While the 2 current commercial clients are sort of somewhat soft in their forecast at the moment, if we can get more similar clients into the Myford facility, clearly that’s going to do a good job of smoothing these revenue flows. We’re fortunate in many ways, even though at times it seems that the commercial mfg. side of things can be heavy lifting and hard work, it’s a lot more choppy & lumpy if you rely entirely on process dev. and clinical stage projects. I do believe we need more of those as well in order to keep the funnel full for pipeline and to keep feeding manufacturing. But, I think if we could, over the shorter term, get in at least 2 more commercial clients and to fill the Myford I facility, I think we’ll see a much smoother revenue flow.
GZ: ”You mentioned some of the aspects of that that you really were attracted to, to be able to take this position. Could you expand on that a little bit? What do you see as a differentiating factor for Avid compared to some of its competitors? Is there going to be a cost benefit, an advantage, efficiency? What do you see as the key advantages of going with Avid vs. competitors?
Roger Lias: That’s a very good question. Differentiation in the, let’s call it the 2,000L single-use bioreactor space is getting tougher & tougher. There were more & more competitive players out there offering on paper at least similar capacity. I think for me, certainly with respect to the particular program that I was assisting with, what was really very impressive was the people, and I have to say that. It was the ability to think creatively out of the box to provide sort of exemplary feedback and that’s a difficult thing to lay out on paper, but once you get potential clients inside the door, I think the team really shines. On top of that, with the program I was involved in I haven’t had the chance to look too carefully at pricing yet, but I think there’s some potential, let’s say, just to increase margins based on pricing. I think Avid is a long way away from being one of the more expensive players out there, which I think is good news, I think it gives us a lot of upside. The available capacity in that long regulatory track record of releasing commercial batches should not be underestimated. There are many, many, I guess I’d call them peer contract manufacturers, who are only just now getting to that stage of their first FDA inspection, and in my view, we should play that for all it’s worth. So I think there’s, from a client perspective, a tremendous opportunity to gain both capacity & expertise at actually pretty reasonable value terms.
GZ: ”And as I recall and correct me if I’m wrong, it’s mostly been bulk mfg. and not so much fill+finish. Do you have any plans to do that?”
Roger Lias: I can’t say we have plans at this point. And again, forgive me as it’s early and I haven’t even had the chance to really discuss this too much with the rest of the team at this point. I do, however, believe that sort of forward integration into drug product manufacture fill+finish is potentially valuable. We have the space to do it. I certainly wouldn’t recommend jumping in heavily into very large scale or anything like that to start off with. It’s a different business; it’s further down the value chain, but nevertheless, we could certainly support clinical fills to support those drug substance clients that are in the clinic, and I think that’s potentially a very good way to start at relatively low investment.
GZ: ”Okay. Roger, welcome and good luck in meeting objectives. I also have a question for Steve regarding bavituximab, because you barely touched on it in your prepared remarks. Could you remind me of what are some of the near-term milestones? Are you going to be presenting anything at SITC’17 [Nov8-12 2017 Natl-Harbor MD], for example, or any other medical conferences?”
Steve King: So for bavituximab, we have a few things on the horizon. Obviously, we recently announced that the NCCN studies are starting to kickoff and one of those I think that’s particularly important is a combination with Keytruda in Head & Neck cancer. Clearly the data, the subset analysis from the SUNRISE trial really supports moving these kind of combinations forward, naturally where we feel that the focus of the program should be in moving forward. In addition, we have other investigators who have expressed interest in running studies that we hopefully would be able to start over the near term with other combinations with the checkpoint inhibitors in actually new indications. And so, those are some of the milestones. Absolutely, you’ll continue to see data coming out at conferences like SITC and AACR and a series of other conferences highlighting both the potential of bavi in combination with checkpoint inhibitors and combinations with cellular therapies such as CAR-T and other cellular therapies that are emerging. I think importantly from the standpoint of finding the right partner for the program, it’s really important that it is a living program and that it is active and that we’re continuing to garner the sort of interest we are from key opinion leaders and from others who really want to see the program advancing and do think it could potentially be a perfect fit with these I/O combinations. So yes, I think you’ll see lots of information coming out. And again, hopefully we’re able to find that right partner here over the short term that will really be able to not just oversee these studies but really boost the program, because it’s very important that we find a partner that’s willing to invest significant dollars upfront here in advancing the program, because we need to really illustrate the proof of concept that the subset analysis from the SUNRISE study is valid. I think that’s an important first step. And then actually move it very quickly toward commercialization because, of course with any drug you get closer & closer rather to your patent expiry and even though those can be extended, there’s a real sense of urgency to see the program move forward very quickly toward those later stage clinical trials. So yes, I look forward to updating on all fronts; the science front, clinical front, as well as the partnering front as we move into the last part of this year.
GZ: ”Okay, thanks. Look forward to seeing those – the new data. Thank you very much.”
MR. KING’S CLOSING COMMENTS:
I’d like to thank you all again for participating in today’s phone call. As always, I want to thank our stockholders for their continued support. And I would like to especially thank our patients, their families, and the investigators that are participating in our bavituximab clinical trials. With that, we will conclude the call.
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = == = = =
9-11-17/PR: Peregrine Pharmaceuticals Reports Financial Results for Q1/FY2018 and Recent Developments
* Avid Bioservices Records Revenues of $27 Million in Q1/FY2018
* Roger Lias, PhD, Appointed President of Avid Bioservices as Company Continues Transition to a CDMO Focused Business
* Supported by Recent Positive Data, Company is Pursuing Strategic Options for its Research and Development Assets
http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=1039958
TUSTIN, Sept. 11, 2017: Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM/PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and through its proprietary R&D pipeline, today announced financial results for the first quarter of fiscal year (FY) 2018 ended July 31, 2017, and provided an update on its contract manufacturing operations, research and development programs, and other corporate highlights.
Highlights Since April 30, 2017
"We have been working diligently toward the transformation from an R&D focused business to a business dedicated to a contract development and manufacturing organization or CDMO. The appointment of Roger Lias, PhD, as President of our CDMO subsidiary, Avid Bioservices, and his appointment to Peregrine's board of directors marks an important next step in this transition [9-11-17/PR: http://tinyurl.com/yd3eh3uv ]. Roger is a highly experienced executive with a long track record of success in the CDMO industry, and was an ideal candidate for the position," stated Steven W. King, President and CEO officer of Peregrine. "We have built a successful commercial CDMO business with an excellent regulatory track record and we look forward to taking Avid to the next level under Roger's leadership. Naturally, job one will be a smooth transition to ensure we continue to support our existing clients while simultaneously working to attract new clients as we look to grow the business on multiple fronts."
Avid Bioservices was established as Peregrine's internal biologics manufacturing and development group, and began formal operations in January 2002. Avid has grown from an internal support operation to a full service CDMO that manufactures bulk drug substance for products that are approved and marketed in over 18 countries by leading biopharma companies. Avid was recently recognized as a leading CDMO by Life Science Leader as a recipient of multiple 2017 Contract Manufacturing Leadership Awards for Quality, Reliability, Capabilities, Expertise and Compatibility. Avid has an outstanding regulatory inspection history and state-of-the-art cGMP manufacturing facilities. Mr. King has been president of Avid since its formation in addition to his role as president and CEO of Peregrine Pharmaceuticals since 2003.
Mr. King continued, "As we focus on the CDMO business, we have been evaluating the best option for divesting our R&D assets through licensing or asset sale. The goal being to find a partner that will make a significant short term investment in the bavituximab program in order to validate the subset analysis from the Phase III SUNRISE trial. The subset analysis, which supports the combination of bavituximab with checkpoint inhibitors, is compelling but needs further clinical validation. These data, combined with findings from our collaborators at Memorial Sloan Kettering Cancer Center (MSKCC – See 4-14-17: http://tinyurl.com/lxlltd6 ) supporting combination with cellular therapy and the ongoing trials from our partners at the National Comprehensive Cancer Network (NCCN), have bolstered our drive to find a suitable partner for advancing the bavituximab and PS-exosome diagnostic programs. We are moving forward expeditiously as we recognize the need to move quickly from the R&D standpoint, as well as the establishment of a pure play CDMO with no R&D expenses. We hope to bring this process to completion over the coming months and will update you on our progress."
Avid Bioservices Highlights
"Avid had a strong first quarter, recognizing revenue of $27 million," stated Paul Lytle, CFO of Peregrine. "When combined with a 57% decrease in R&D spending and a moderate decrease in SG&A, our net loss for the quarter decreased 89% to $1.2 million. During this transition year where we have seen a lower manufacturing demand from our top two customers, we are still expecting to generate between $50 and $55 million in revenue while we continue to focus on securing new customers and diversifying our customer base as we have added four new customers this calendar year thus far."
* The company is providing manufacturing revenue guidance for the full FY 2018 of $50-55 million.
* Avid's current manufacturing revenue backlog is $33 million, representing estimated future manufacturing revenue to be recognized under committed contracts. Most of the backlog is expected to be recognized during the remainder of FY 2018.
Research & Development Highlights
ASCO Highlights:
Peregrine researchers presented additional supportive data demonstrating that patients in the bavituximab containing arm who had low baseline PD-L1 expression on tumor cells (i.e., patients typically with poorer response to PD-1/PD-L1 checkpoint inhibitors) lived significantly longer than patients with high baseline PD-L1 expression. [6-3-17: http://tinyurl.com/y93upatl ]
ESMO Highlights:
Clinical investigators and Peregrine researchers presented the final clinical results from the company's Phase III SUNRISE trial of bavituximab in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer. As previously reported, study results demonstrated that the addition of bavituximab to docetaxel did not result in improvement of the study's primary endpoint of overall survival in the intent-to-treat population. However, a subgroup analysis on the final dataset demonstrated that for bavituximab plus docetaxel patients who received subsequent immunotherapy, the median overall survival was not yet reached. This compared to a median overall survival of 12.6 months for patients who received placebo plus docetaxel, and subsequent immunotherapy [HR = 0.46; p = 0.006]. [9-9-17: http://tinyurl.com/yb9kjutp ]
NCCN Highlights:
The three clinical trials under the collaboration with the NCCN are advancing as planned.
* Massachusetts General Hospital Cancer Center—Phase I/II Clinical Trial of Bavituximab with Radiation and Temozolomide for Patients with Newly Diagnosed Glioblastoma. Patient dosing was initiated in September 2017.
* Moffitt Cancer Center—A Phase I Trial of Sorafenib and Bavituximab Plus Stereotactic Body Radiation Therapy for Unresectable Hepatitis C Associated Hepatocellular Carcinoma. This trial is open for enrollment.
* The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins—Phase II Study of Pembrolizumab and Bavituximab for Progressive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. This trial is expected to be initiated by the end of the calendar year 2017.
PS Exosome Technology Highlights:
The company continues to make progress with its PS exosome diagnostic technology that is designed to detect and monitor cancer. The assay has been successfully optimized and we are evaluating options to license, partner, or sell this technology. [7-15-17: http://tinyurl.com/yd3n5kbk ]
Financial Highlights and Results
Contract manufacturing revenue from Avid's clinical and commercial biomanufacturing services was $27,077,000 for the first quarter of FY 2018 compared to $5,609,000 for the first quarter of FY 2017. This represents total revenue growth of 383% for FY 2018 compared to the same prior year period. It is important to note that the $27 million included the shipment of $10 million in product, which was held over from the fourth quarter of 2017 due to delays in shipping at the customer's request. The first quarter increase was primarily attributed to an increase in demand for contract manufacturing services associated with process validation activities in addition to the greater number of manufacturing runs shipped during the quarter.
Total costs and expenses for the first quarter of FY 2018 were $28,306,000, compared to $16,691,000 for the first quarter of FY 2017. Research and development expenses decreased 57% to $3,645,000, compared to $8,569,000 for the first quarter of FY 2017.
Cost of contract manufacturing increased to $20,448,000 in the first quarter of FY 2018 compared to $3,062,000 for the first quarter of FY 2017. This increase is primarily due to an increase in the cost of contract manufacturing associated with higher reported revenue. Also contributing to this increase and impacting gross margins for the period was idle capacity due to lower demand and unavailable capacity during the installation of the new 2,000 liter bioreactors combined with a higher percentage of revenue related to pass through charges, such as raw materials, that are recorded as revenue at cost plus a nominal mark-up, thereby lowering the overall gross margin. During the current quarter, 38% of our revenue was related to pass-through charges versus 20% in the same prior year quarter. For the first quarter of FY 2018, selling, general and administrative expenses decreased to $4,213,000 compared to $5,060,000 for FY 2017. Peregrine's consolidated net loss attributable to common stockholders was $2,647,000 or $0.06 per share, for the first quarter of FY 2018, compared to a net loss attributable to common stockholders of $12,437,000, or $0.36 per share, for the same prior year quarter. Peregrine reported $37,256,000 in cash and cash equivalents as of July 31, 2017, compared to $46,799,000 at fiscal year ended April 30, 2017.
More detailed financial information and analysis may be found in Peregrine's Quarterly Report on Form 10-Q, which will be filed with the Securities and Exchange Commission today.
[ https://www.sec.gov/Archives/edgar/data/704562/000168316817002343/peregrine_10q-073117.htm ]
CONFERENCE CALL: Peregrine will host a conference call and webcast this afternoon, Sept. 11, 2017, at 4:30PM EDT (1:30PM PDT). To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals conference call. To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm .
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development and manufacturing organization (CDMO) services and through its proprietary R&D pipeline. Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com ), which provides development and biomanufacturing services for both Peregrine and third-party customers. The company is also working to evaluate its lead immunotherapy candidate, bavituximab, in combination with immune stimulating therapies for the treatment of various cancers, and developing its proprietary exosome technology for the detection and monitoring of cancer. For more information, please visit http://www.peregrineinc.com .
About Avid Bioservices
Avid Bioservices provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 15 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit http://www.avidbio.com .
Safe Harbor *snip*
CONTACTS:
• Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com
• Tim Brons (Media) Vida Strategic Partners 415-675-7402 tbrons@vidasp.com
PEREGRINE PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)
THREE MONTHS ENDED
JULY 31,
2017 2016
Contract manufacturing revenue $ 27,077,000 $ 5,609,000
COSTS AND EXPENSES:
Cost of contract manufacturing 20,448,000 3,062,000
Research and development 3,645,000 8,569,000
Selling, general and administrative 4,213,000 5,060,000
Total costs and expenses 28,306,000 16,691,000
LOSS FROM OPERATIONS (1,229,000 ) (11,082,000 )
OTHER INCOME (EXPENSE):
Interest and other income 27,000 25,000
Interest and other expense (3,000 ) —
NET LOSS $ (1,205,000 ) $ (11,057,000 )
COMPREHENSIVE LOSS $ (1,205,000 ) $ (11,057,000 )
Series E preferred stock accumulated dividends (1,442,000 ) (1,380,000 )
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS
$ (2,647,000 ) $(12,437,000)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic and diluted (1) 44,773,727 34,227,870
BASIC AND DILUTED LOSS PER COMMON SHARE (1) $ (0.06 ) $ (0.36 )
(1) All share and per share amounts of our common stock for all periods presented have been retroactively adjusted to reflect the one-for-seven reverse stock split of our issued and outstanding common stock, which took effect with the opening of trading on July 10, 2017.
PEREGRINE PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
JULY 31, 2017 APRIL 30,
2017 Unaudited
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 37,256,000 $ 46,799,000
Trade and other receivables 7,884,000 7,742,000
Inventories 24,235,000 33,099,000
Prepaid expenses 1,388,000 1,460,000
Total current assets 70,763,000 89,100,000
Property and equipment, net 24,399,000 23,674,000
Restricted cash 1,150,000 1,150,000
Other assets 3,963,000 4,188,000
TOTAL ASSETS $ 100,275,000 $ 118,112,000
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable $ 4,013,000 $ 5,779,000
Accrued clinical trial and related fees 4,812,000 4,558,000
Accrued payroll and related costs 4,844,000 6,084,000
Deferred revenue 13,433,000 28,500,000
Customer deposits 14,322,000 17,017,000
Other current liabilities 963,000 993,000
Total current liabilities 42,387,000 62,931,000
Deferred rent, less current portion 1,880,000 1,599,000
Commitments and contingencies
STOCKHOLDERS' EQUITY (1):
Preferred stock—$0.001 par value; authorized 5,000,000 shares; 1,647,760 issued and outstanding at July 31, 2017 and April 30, 2017, respectively 2,000 2,000
Common stock—$0.001 par value; authorized 500,000,000 shares; 45,094,154 and 44,014,040 issued and outstanding at July 31, 2017 and April 30, 2017, respectively 45,000 44,000
Additional paid-in capital 594,482,000 590,971,000
Accumulated deficit (538,521,000 ) (537,435,000 )
Total stockholders' equity 56,008,000 53,582,000
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 100,275,000 $ 118,112,000
(1) All share and per share amounts of our common stock for all periods presented have been retroactively adjusted to reflect the 1:7 reverse stock split of our issued and outstanding common stock, which took effect with the opening of trading on July 10, 2017.
- - - - - - - -
From 10-Q header: “As of Sept. 6, 2017, there were 45,096,081 shares outstanding.”
- - - - - - - - - - - - - - - - -
Latest 10K 4-30-17 iss. 7-14-17 http://tinyurl.com/ycxu4l5n PR: http://tinyurl.com/yb4wulvu (Cash 4-30-17=$46.8mm); Amended 8-25-17: http://tinyurl.com/yb5jq7vc
Latest 10Q 7-31-17 iss. 9-11-17 http://tinyurl.com/ycbzp4zn PR: http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=1039958 (Cash 7-31-17=$37.3mm)
ALL SEC filings for PPHM: http://tinyurl.com/6d4jw8
9-11-17: O/S Shares & ATM Sales History (’06–curr.) http://tinyurl.com/ybjgm425
**NOTES:
1. PPHM shares were 1:7 Reverse Split eff. 7-10-17 (~315mm/$.606=>~45mm/$4.24) http://tinyurl.com/ycohqn6j
2. Per the 4-30-10 10-K (pub. 7-14-17), ALL ATM Agreements have been fully used – none remain (F-20 & F-28). If any new ATM’s are opened (and reported via Form 424B5), they go against the $67mm remaining on the orig. $150mm shelf filed via the S-3 filed 4-23-14. 10K: http://tinyurl.com/ycxu4l5n
3. The last ATM sales made (a/o the 7-31-17 10Q iss 9-11-17) were these: • Sold 5/1/17-6/30/17: $4,307,000gr./1,051,258sh. = $4.10/sh.
= = = = = = = = = = = = = = = = = = = = = = = = = = = =
Updated PPHM REVS-BY-QTR TABLE, now thru FY18'Q1(qe 7-31-17), per the 10-Q ( http://tinyurl.com/ycbzp4zn ) issued 9-11-17.
• Total Revs since May’06: ($258.3mm/Avid + $24.1mm/Govt + $2.5mm/Lic.) = $284.9mm
• 9-11-17: FY'18 (May'17-Apr'18) Avid revs guidance $50-55mm (committed B/L=$33mm). **
• Deferred-Revs at 7-31-17 total $15.1mm, DOWN from $28.5mm at 4-30-17.
• Cust.Deposits at 7-31-17 total $2.7mm, DOWN from $17.0mm at 4-30-17.
• Inventories at 7-31-17 total $24.2mm, DOWN from $33.1mm at 4-30-17.
• Avid’s Gross-Profit over last 4 qtrs: $23.5mm on revs of $79.1mm (GP%=29.7)
• Recall, Avid Rev$ from Gov’t DTRA Contract work (6/30/08 – 4/15/11, totaling $24.15mm), went into GOVT-REVS, not AVID-REVS, in the Financials.
**4-30-17 10K/p.33: “Excluding any future potential new business, we expect Avid revs for FY18 [$50-55mm guidance] to slightly decline vs. FY17. Part of this decline is due to lower anticipated commitments from Halozyme (our largest customer) based on their most recent committed forecast (covering the 3 qtrs ending March 2018), which amount is expected to be partially offset by $10mm revenue that was expected to be recognized in FY17, but has been shifted to FY18 due to a delay in shipping product that was complete & ready for shipment as of fye 4-30-17. http://tinyurl.com/ycxu4l5n
Avid’s website: http://www.avidbio.com
AVID PROFITABILITY (GROSS*) BY QTR:
QTR Avid-Rev$ CostofMfg$ Gross-Profit$ GP%
FY13Q1 7-31-12 4,135,000 2,024,000 2,111,000 51%
FY13Q2 10-31-12 6,061,000 3,703,000 2,358,000 39%
FY13Q3 1-31-13 6,961,000 3,651,000 3,310,000 47%
FY13Q4 4-30-13 4,176,000 3,217,000 959,000 23%
FY14Q1 7-31-13 4,581,000 2,670,000 1,911,000 42%
FY14Q2 10-31-13 7,354,000 4,195,000 3,159,000 43%
FY14Q3 1-31-14 3,885,000 2,416,000 1,469,000 38%
FY14Q4 4-30-14 6,474,000 3,829,000 2,645,000 41%
FY15Q1 7-31-14 5,496,000 3,583,000 1,913,000 35%
FY15Q2 10-31-14 6,263,000 4,139,000 2,124,000 34%
FY15Q3 1-31-15 5,677,000 3,113,000 2,564,000 45%
FY15Q4 4-30-15 9,308,000 4,758,000 4,550,000 49%
FY16Q1 7-31-15 9,379,000 4,608,000 4,771,000 51%
FY16Q2 10-31-15 9,523,000 4,741,000 4,782,000 50%
FY16Q3 1-31-16 6,672,000 3,896,000 2,776,000 42%
FY16Q4 4-30-16 18,783,000 9,721,000 9,062,000 48%
FY17Q1 7-31-16 5,609,000 3,062,000 2,547,000 45%
FY17Q2 10-31-16 23,370,000 15,441,000 7,929,000 34%
FY17Q3 1-31-17 10,747,000 7,974,000 2,773,000 26%
FY17Q4 4-30-17 17,904,000 11,782,000 6,122,000 34%
FY18Q1 7-31-17 27,077,000 20,448,000 6,629,000 24%
FY13 TOTAL: 21,333,000 12,595,000 8,738,000 41%*
FY14 TOTAL: 22,294,000 13,110,000 9,184,000 41%*
FY15 TOTAL: 26,744,000 15,393,000 11,151,000 42%*
FY16 TOTAL: 44,357,000 22,966,000 21,391,000 48%*
FY17 TOTAL: 57,630,000 38,259,000 19,371,000 34%*
*Avid Net-Profit (ie, incl. Selling, G&A) not split out from PPHM-Corp. in the financials.
.
PPHM REVENUES (in thousands) DEFERRED
-------REVENUES------- REVENUES INVEN-
Quarter Avid Govt Lic. TOTAL Avid Govt TORIES
FY07Q1 7-31-06 398 0 23 421 317 0 971
FY07Q2 10-31-06 636 0 48 684 1388 0 1899
FY07Q3 1-31-07 347 0 16 363 2202 0 1325
FY07Q4 4-30-07 2111 0 129 2240 1060 0 1916
FY08Q1 7-31-07 1621 0 4 1625 1820 0 2363
FY08Q2 10-31-07 1863 0 29 1892 1338 0 3500
FY08Q3 1-31-08 1662 0 13 1675 1434 0 2394
FY08Q4 4-30-08 751 0 150 901 2196 0 2900
FY09Q1 7-31-08 1193 324 0 1517 4021 980 4628
FY09Q2 10-31-08 983 958 0 1941 6472 1701 6700
FY09Q3 1-31-09 5778 1048 0 6826 4805 3262 5547
FY09Q4 4-30-09 5009 2683 175 7867 3776 3871 4707
FY10Q1 7-31-09 2070 4671 9 6750 5755 2332 6177
FY10Q2 10-31-09 5308 1510 78 6896 4260 3989 5850
FY10Q3 1-31-10 2945 6854 78 9877 3052 76 3861
FY10Q4 4-30-10 2881 1461 78 4420 2406 78 3123
FY11Q1 7-31-10 983 2111 115 3209 3719 47 4692
FY11Q2 10-31-10 3627 966 78 4671 2447 35 3555
FY11Q3 1-31-11 1922 882 79 2883 4300 40 3915
FY11Q4 4-30-11 1970 681 78 2729 5617 0 5284
FY12Q1 7-31-11 5439 0 216 5655 4145 0 4481
FY12Q2 10-31-11 4154 0 78 4232 2012 0 3178
FY12Q3 1-31-12 3203 0 78 3281 2552 0 2722
FY12Q4 4-30-12 1987 0 78 2065 3651 0 3611
FY13Q1 7-31-12 4135 0 116 4251 6056 0 5744
FY13Q2 10-31-12 6061 0 78 6139 6221 0 5426
FY13Q3 1-31-13 6961 0 78 7039 5061 0 4635
FY13Q4 4-30-13 4176 0 78 4254 4171 0 4339
FY14Q1 7-31-13 4581 0 107 4688 4164 0 5679
FY14Q2 10-31-13 7354 0 0 7354 3468 0 4033
FY14Q3 1-31-14 3885 0 0 3885 4329 0 5224
FY14Q4 4-30-14 6474 0 0 6474 5241 0 5530
FY15Q1 7-31-14 5496 0 0 5496 4670 0 5998
FY15Q2 10-31-14 6263 0 37 6300 3612 0 5379
FY15Q3 1-31-15 5677 0 0 5677 5752 0 6148
FY15Q4 4-30-15 9308 0 0 9308 6630 0 6148
FY16Q1 7-31-15 9379 0 292 9671 8291 0 10457
FY16Q2 10-31-15 9523 0 0 9523 9688 0 12554
FY16Q3 1-31-16 6672 0 37 6709 15418 0 15189
FY16Q4 4-30-16 18783 0 0 18783 15418 0 15189
FY17Q1 7-31-16 5609 0 0 5609 21531 0 25274
FY17Q2 10-31-16 23370 0 0 23370 21531 0 25274
FY17Q3 1-31-17 10747 0 0 10747 26367 0 33829
FY17Q4 4-30-17 17904 0 0 17904 28500 0 33099
FY18Q1 7-31-17 27077 0 0 27077 13433 0 24235
Totals: 258276 24149 2453 284878 <=since5/1/2006
.
TOTAL REV’s BY YEAR (Avid+Gov’t+Lic):
FY04 4-30-04 3,314 …Avid(CMO)= 3,039 (Avid-Revs don’t incl. Govt-SVCS)
FY05 4-30-05 4,959 …Avid(CMO)= 4,684
FY06 4-30-06 3,193 …Avid(CMO)= 3,005
FY07 4-30-07 3,708 …Avid(CMO)= 3,492
FY08 4-30-08 6,093 …Avid(CMO)= 5,897
FY09 4-30-09 18,151 …Avid(CMO)= 12,963
FY10 4-30-10 27,943 …Avid(CMO)= 13,204
FY11 4-30-11 13,492 …Avid(CMO)= 8,502
FY12 4-30-12 15,233 …Avid(CMO)= 14,783
FY13 4-30-13 21,683 …Avid(CMO)= 21,333
FY14 4-30-14 22,401 …Avid(CMO)= 22,294
FY15 4-30-15 26,781 …Avid(CMO)= 26,744
FY16 4-30-16 44,686 …Avid(CMO)= 44,357
FY17 4-30-17 57,630 …Avid(CMO)= 57,630
...Total Gov’t Revs from 7-2008 inception thru FY11Q1(Apr’11): $24.15mm
.
PPHM’S QTLY. NET LOSS BY QTR:
FY08Q1 7-31-07 4,656,000
FY08Q2 10-31-07 6,207,000
FY08Q3 1-31-08 6,154,000
FY08Q4 4-30-08 6,159,000
FY09Q1 7-31-08 5,086,000
FY09Q2 10-31-08 4,497,000
FY09Q3 1-31-09 3,332,000
FY09Q4 4-30-09 3,609,000
FY10Q1 7-31-09 2,428,000
FY10Q2 10-31-09 2,787,000
FY10Q3 1-31-10 1,538,000
FY10Q4 4-30-10 7,741,000
FY11Q1 7-31-10 7,695,000
FY11Q2 10-31-10 7,513,000
FY11Q3 1-31-11 8,929,000
FY11Q4 4-30-11 10,014,000
FY12Q1 7-31-11 8,092,000
FY12Q2 10-31-11 12,055,000
FY12Q3 1-31-12 11,090,000
FY12Q4 4-30-12 10,882,000
FY13Q1 7-31-12 7,664,000
FY13Q2 10-31-12 8,753,000
FY13Q3 1-31-13 4,914,000
FY13Q4 4-30-13 8,449,000
FY14Q1 7-31-13 7,600,000
FY14Q2 10-31-13 7,790,000
FY14Q3 1-31-14 9,724,000
FY14Q4 4-30-14 10,248,000
FY15Q1 7-31-14 13,129,000
FY15Q2 10-31-14 12,100,000
FY15Q3 1-31-15 12,994,000
FY15Q4 4-30-15 12,135,000
FY16Q1 7-31-15 13,723,000
FY16Q2 10-31-15 13,198,000
FY16Q3 1-31-16 16,847,000
FY16Q4 4-30-16 11,884,000
FY17Q1 7-31-16 11,057,000
FY17Q2 10-31-16 4,056,000
FY17Q3 1-31-17 7,774,000
FY17Q4 4-30-17 5,272,000
FY18Q1 7-31-17 1,205,000
= = = = = = = =
OPER. CASH BURNS* BY QTR(FROM THE 10-Q/K’S):
FY10Q1 7-31-09 2,024,000 (from 10Q pg.25)
FY10Q2 10-31-09 2,351,000 (Q1+Q2: 4,375,000 pg.28)
FY10Q3 1-31-10 1,158,000 (Q1+Q2+Q3: 5,533,000 pg.30)
FY10Q4 4-30-10 6,375,000 (FY’10: 11,908,000 10K pg.58)
FY11Q1 7-31-10 6,567,000 (from 10Q pg.24)
FY11Q2 10-31-10 6,167,000 (Q1+Q2: $12,734,000 pg.25)
FY11Q3 1-31-11 7,736,000 (Q1+Q2+Q3: $20,470,000 pg.26)
FY11Q4 4-30-11 8,961,000 (FY’11: 29,431,000 10K pg.54)
FY12Q1 7-31-11 6,984,000 (from 10Q pg.25)
FY12Q2 10-31-11 11,668,000 (Q1+Q2: 18,652,000 pg.25)
FY12Q3 1-31-12 8,490,000 (Q1+Q2+Q3: 27,142,000 pg.25)
FY12Q4 4-30-12 11,265,000 (FY’12: 38,407,000 10K pg.55)
FY13Q1 7-31-12 6,742,000 (from 10Q pg.21)
FY13Q2 10-31-12 6,162,000 (Q1+Q2: 12,904,000 pg.23)
FY13Q3 1-31-13 3,597,000 (Q1+Q2+Q3: 16,501,000 pg.23)
FY13Q4 4-30-13 7,053,000 (FY’13: 23,554,000 10K pg.60)
FY14Q1 7-31-13 5,750,000 (from 10Q pg.23)
FY14Q2 10-31-13 5,834,000 (Q1+Q2: 11,584,000 10Q pg.24)
FY14Q3 1-31-14 7,875,000 (Q1+Q2+Q3: 19,459,000 10Q pg.26)
FY14Q4 4-30-14 8,706,000 (FY’14: 28,165,000 10K pg.55)
FY15Q1 7-31-14 11,076,000 (from 10Q pg.23)
FY15Q2 10-31-14 9,947,000 (Q1+Q2: 21,023,000 10Q pg.25)
FY15Q3 1-31-15 11,116,000 (Q1+Q2+Q3: 32,139,000 10Q pg.26)
FY15Q4 4-30-15 10,474,000 (FY’15: 42,613,000 10K pg.54)
FY16Q1 7-31-15 12,306,000 (from 10Q pg.25)
FY16Q2 10-31-15 11,701,000 (Q1+Q2: 24,007,000 10Q pg.26)
FY16Q3 1-31-16 15,086,000 (Q1+Q2+Q3: 39,093,000 10Q pg.27)
FY16Q4 4-30-16 10,112,000 (FY'16: 49,205,000 10K pg.39)
FY17Q1 7-31-16 9,607,000 (from 10Q pg.22)
FY17Q2 10-31-16 2,565,000 (Q1+Q2: 12,172,000 10Q pg.24)
FY17Q3 1-31-17 6,274,000 (Q1+Q2+Q3: 18,446,000 10Q pg.24)
FY17Q4 4-30-17 3,886,000 (FY'17: 22,332,000 10K pg.40)
FY18Q1 7-31-17 78,000 (from 10Q pg.23)
FY’09 total Op-Burn: $14,715,000
FY’10 total Op-Burn: $11,908,000
FY’11 total Op-Burn: $29,431,000
FY’12 total Op-Burn: $38,407,000
FY’13 total Op-Burn: $23,554,000
FY’14 total Op-Burn: $28,165,000
FY’15 total Op-Burn: $42,613,000
FY’16 total Op-Burn: $49,205,000
FY’17 total Op-Burn: $22,332,000
Period Halozyme Cust-A Other-Custs
FYE 4-30-14 91% 1% 8%
FYE 4-30-15 79% 12% 9%
FYE 4-30-16 69% 26% 5%
Q/E 7-31-16 65% 29% 6%
Q/E 10-31-16 77% 10% 13%
Q/E 1-31-17 29% 56% 15%
FYE 4-30-17 58% 26% 16%
Q/E 7-31-17 78% 16% 16%
O/S Shares & ATM Sales History (’06–curr.)
Shares O/S as of 9-6-17: 45,096,081
**NOTES:
1. PPHM shares were 1:7 Reverse Split eff. 7-10-17 (~315mm/$.606=>~45mm/$4.24) http://tinyurl.com/ycohqn6j
2. Per the 4-30-10 10-K (iss. 7-14-17), ALL ATM Agreements had been fully used – none remained (F-20 & F-28). If any new ATM’s are opened (and reported via Form 424B5), they go against the $67mm remaining on the orig. $150mm shelf filed via the S-3 filed 4-23-14. 10K: http://tinyurl.com/ycxu4l5n
-------
NOTE: the 7-31-17 10Q (iss. 9-11-17 http://tinyurl.com/ycbzp4zn ) confirmed this: NO ATM SALES OCCURRED AFTER THOSE REPORTED IN THE “SUBSEQUENT EVENTS” SECTION OF THE 4-30-17 10K (iss. 7-14-17) – these were the last ATM’s sold:
• Sold 5/1/17-6/30/17: $4,307,000gr. / 7,358,806(1,051,258 post/RS)= $.59/sh.($4.10/sh. Post/RS)
PPHM - O/S Shares History (’06–curr.)
4-30-06 35,876,438
1-31-07 39,222,440
4-30-07 39,222,440
7-6-07 45,233,123
7-31-07 45,242,123
10-31-07 45,242,123
1-31-08 45,242,123
4-30-08 45,242,123
7-31-08 45,242,123
10-31-08 45,242,123
1-31-09 45,242,123
4-30-09 45,537,711
7-10-09 47,392,883
7-31-09 47,393,783
**NOTE: PPHM shares were 1:5 Reverse Split eff. 10-19-09 (~237mm/$.64=>~47.4mm/$3.20) http://tinyurl.com/ykuw588
10-31-09 48,869,563 +1,475,780
1-31-10 50,903,404 +2,033,841
4-30-10 53,094,894 +2,191,490
6-21-10 54,388,917 +1,294,023 (6-22-10 ATM/mlv Form424)
7-9-10 55,069,449 +475,987 (4-30-10 10K iss. 7-14-10)
7-31-10 55,784,955 +715,506
10-31-10 59,220,742 +3,435,787
11-30-10 63,932,353 +4,711,611 (10-31-10 10Q iss. 12-9-10)
12-15-10 64,404,097 +471,744 (12-17-10 S-3: $75M Shelf Reg.)
1-31-11 66,813,419 +2,409,322
2-28-11 67,885,811 +1,072,392 (1-31-11 10Q iss. 3-11-11)
4-30-11 69,837,142 +1,951,331
7-8-11 71,069,858 +1,232,716 (4-30-11 10K iss. 7-14-11)
8-22-11 72,704,647 +1,634,789 (Proxy iss. 8-26-11)
8-31-11 73,284,016 +579,369 (424B5 iss. 9-2-11)
9-8-11 79,536,268 +6,252,252 (Roth Sale to 3 Inst’s @ $1.11/sh.)
10-31-11 82,638,201 +3,101,933
12-9-11 86,788,817 +4,150,616 (10-31-11 10Q iss. 12-12-11)
1-31-12 93,146,226 +6,357,409
2-29-12 98,873,172 +5,726,946 (1-31-12 10Q iss. 3-9-12)
4-30-12 101,421,365 +2,548,193
7-13-12 104,174,056 +2,752,691 (4-30-12 10K iss. 7-16-12)
7-31-12 104,178,431 +4,375 (7-31-12 10Q iss. 9-10-12)
8-16-12 104,191,176 +12,745 (prelim. proxy 14A http://tinyurl.com/c48bvof )
9-7-12 104,191,176 nochg (7-31-12 10Q iss. 9-10-12)
10-31-12 123,310,188 +19,119,012
12-7-12 132,539,783 +9,229,595 (10-31-12 10Q iss. 12-10-12)
1-31-13 133,770,614 +1,230,831
3-12-13 137,110,758 +3,340,144 (1-31-13 10Q iss. 3-12-13)
4-30-13 143,768,946 +6,658,188 (4-30-13 10K iss. 7-11-13)
7-5-13 151,602,765 +7,833,819 (4-30-13 10K iss. 7-11-13)
7-31-13 153,506,811 +1,904,046
9-5-13 156,461,114 +2,954,303 (7-31-13 10K iss. 9-9-13)
10-31-13 160,248,742 +3,781,628
12-6-13 160,325,891 +77,149 (10-31-13 10K iss. 12-10-13)
1-31-14 176,453,261 +16,127,370
3-3-14 176,481,054 +27,793 (1-31-14 10Q iss. 3-7-14)
4-30-14: 178,871,164 +2,390,110
7-7-14: 179,209,458 +338,294 (4-30-14 10-K cover page, iss. 7-14-14)
7-31-14: 179,216,032 +6,574 (7-31-14 10Q iss. 9-9-14)
8-22-14: 179,226,424 +10,392 (8-28-14 Proxy/Def14A)
9-5-14: 179,505,424 +279,000 (7-31-14 10Q iss. 9-9-14)
10-31-14: 182,000,583 +2,495,159 (10-31-14 10Q iss. 12-10-14)
12-5-14: 182,081,234 +80,651 (10-31-14 10Q cover pg., iss. 12-10-14)
12-19-14: 182,081,234 -0- (12-23-14 S-3)
1-31-15: 184,244,698 +2,163,464 (1-31-15 10Q iss. 3-12-15)
3-12-15: 188,332,872 +4,088,174 (“ “ “)
4-30-15: 193,346,627 +5,013,755 (4-30-15 10-K iss. 7-14-15)
7-10-15: 199,934,918 +6,588,291 (4-30-15 10-K/cover-pg, iss. 7-14-15)
7-31-15: 200,983,948 +1,049,030 (7-31-15 10Q iss. 9-9-15)
9-4-15: 202,124,031 +1,140,083 (“ “ “)
10-31-15: 225,824,551 +23,700,520 (10-31-15 10Q iss. 12-10-15)<=Incl. 18.5mm sh. Dart/EastCAP @1.08
12-9-15: 229,701,808 +3,877,257 (10-31-15 10Q iss. 12-10-15)
1-31-16: 232,231,242 +2,529,434 (1-31-16 10Q iss. 3-9-16)
3-8-16: 233,738,426 +1,507,184 (“ “ “)
4-30-16: 236,930,485 +3,192,059 (4-30-16 10K iss. 7-14-16)
7-11-16: 241,456,721 +4,526,236 (“ “ “)
7-31-16: 241,456,721 -0- (7-31-16 10Q iss. 9-8-16)
9-2-16: 242,381,850 +925,129 (“ “ “)
10-31-16: 251,765,279 +9,383,429 (10-31-16 10Q iss. 12-12-16)
12-8-16: 257,141,534 +5,376,255 (“ “ “)
1-31-17: 271,068,464 +13,926,930 (1-31-17 10Q iss. 3-13-17)
3-10-17: 297,709,478 +26,641,014 (“ “ “)
4-30-17: 44,014,040(x7)=308,098,280 +10,388,802 (4-30-17 10K iss. 7-14-17)
7-10-17: 1:7 R/S (~315mm/$.606=>~45mm/$4.24) http://tinyurl.com/ycohqn6j
7-10-17: 45,069,188 +1,055,148 (“ “ “)
7-31-16: 45,094,154 +24,966 (7-31-17 10Q iss. 9-11-17)
8-25-17: 45,096,081 +1,927 (8-25-17 Amended 10K http://tinyurl.com/yb5jq7vc )
9-6-17: 45,096,081 nochg (7-31-17 10Q iss. 9-11-17)
= = = = = = = = = = = = = = = = = =
ATM Sales Summary (3/2009–9/11/2017). Also, PPHM O/S Shares History Table (’06–curr.) at the bottom of this post. At 9-6-17, common shares O/S = 45,096,081sh. (recall, 1:7 R/S was eff. 7-10-17)
ATM = “At-The-Market Sales Issuance”
-------
The 7-31-17 10Q (iss. 9-11-17 http://tinyurl.com/ycbzp4zn ) confirmed that NO ATM SALES OCCURRED AFTER THOSE REPORTED IN THE “SUBSEQUENT EVENTS” SECTION OF THE 4-30-17 10K (iss. 7-14-17) – these were the last ATM’s sold:
• Sold 5/1/17-6/30/17: $4,307,000gr. / 7,358,806(1,051,258 post/RS)= $.59/sh.($4.10/sh. Post/RS)
I. WM-SMITH 3-2009:
• $7.5mm ATM/Wm.SMITH 3-26-09: $7,500,000gr. / 2,150,759sh. = $3.49/sh. (commiss: 3%)
• $25mm ATM/Wm.SMITH 7-14-09: $25,000,000gr. / 7,569,314sh. = $3.30/sh. (commiss: 3%/1st$15mm, then 2%)
*Total Raised via WmSmith ATM Sales thru 7-31-10:
. . .Before 7-10-17 1:7RS: $32,500,000gr. / 9,720,073sh. = $3.34/sh.
. . .After 7-10-17 1:7RS: $32,500,000gr. / 1,388,582sh. = $23.41/sh.
II. MLV 6-2010: http://www.mlvco.com
$15mm ATM/MLV 6-22-10 (commiss: 2%) Form424: http://tinyurl.com/24txkxb
• Sold 6/22/10–10/31/10: $6,840,000gr. / 4,031,018sh. = $1.70/sh.
• Sold 11/1/10–11/30/10: $7,407,000gr. / 4,711,611sh. = $1.57/sh.
• Sold 12/1/10–1/31/11: $753,000gr. / 471,744sh. = $1.60/sh.
*Total Raised via MLV June’10 ATM Sales thru 1-31-11:
. . .Before 7-10-17 1:7RS: $15,000,000gr. / 9,214,373 = $1.63/sh.
. . .After 7-10-17 1:7RS: $15,000,000gr. / 1,316,339 = $11.40/sh.
III. MLV 12-2010: “Dec’10 AMI Agreement” http://www.mlvco.com
$75mm ATM/MLV 12-29-10 (commiss: max=5%) Form8K: http://tinyurl.com/2a6w76g
(pursuant to $75mm S-3 Shelf Reg. filed 12-17-10: http://tinyurl.com/2469b2d )
• Sold 12/29/10-1/31/11: $6,460,000gr. / 2,385,862sh. = $2.71/sh.
• Sold 2/1/11-2/28/11: $2,358,000gr. / 998,142sh. = $2.36/sh.
• Sold 3/1/11-4/30/11: $4,470,000gr. / 1,840,487sh. = $2.43/sh.
• Sold 5/1/11-7/31/11: $3,713,000gr. / 1,912,576sh. = $1.94/sh.
• Sold 8/1/11-10/31/11: $5,582,000gr. / 4,727,840sh. = $1.18/sh.
• Sold 9-2-12 Roth Direct: $6,940,000gr./ 6,252,252sh. = $1.11/sh.
• Sold 11/1/11-1/31/12: $10,961,000gr. / 10,308,025sh. = $1.06/sh.
• Sold 2/1/12-2/29/12: $5,871,000gr. / 5,726,946sh. = $1.03/sh.
• Sold 3/1/12-4/30/12: $1,263,000gr. / 2,198,543sh. = $.57/sh.
• Sold 5/1/12-6/30/12: $1,496,000gr. / 2,752,691sh. = $.54/sh.
• Sold 7/1/12-9/26/12: none**
• Sold 9/27/12-10/31/12: $16,719,000gr./ 18,557,928 = $.90/sh.
• Sold 11/1/12-11/30/12: $7,296,000gr./ 9,220,313 = $.79
• Sold 12/1/12-1/31/13: $1,540,000gr./ 1,131,282 = $1.36
• Sold 2/1/13-3/12/13: $330,000gr./ 201,154 = $1.64
*Total Raised via MLV Dec’10 ATM Sales thru 3-12-2013:
. . .Before 7-10-17 1:7RS: $75,000,000gr. / 68,214,041 = $1.10sh.
. . .After 7-10-17 1:7RS: $75,000,000gr. / 9,744,863 = $7.70sh.
IV. MLV 12-2012: “Dec’12 AMI Agreement” http://www.mlvco.com
$75mm ATM/MLV 12-29-12 (commiss: max=5%) Form8K: http://tinyurl.com/2a6w76g
(pursuant to $75mm S-3 Shelf Reg. filed 3-9-12: http://tinyurl.com/7dl7pjm )
• Sold 2/1/13-3/12/13: $4,475,000gr. / 3,132,402sh. = $1.43/sh.
• Sold 3/13/13-4/30/13: $8,897,000gr. / 6,188,273sh. = $1.44/sh.
• Sold 5/1/13-7/11/13: $12,729,000gr. / 7,927,016sh. = $1.61/sh.
• Sold 7/12/13-7/31/13: $2,468,000gr. / 1,690,864sh. = $1.46/sh.
• Sold 8/1/13-9/9/13: $4,372,000gr. / 3,057,431sh. = $1.43/sh.
• Sold 9/10/13-10/31/13: $4,708,000gr. / 3,262,958sh. = $1.44/sh.
• Sold 11/1/13-12/6/13: NONE – see 10Q note below.
• Sold 12/7/13-1/31/14: $28,130,000gr. / 16,045,717sh. = $1.75/sh.
• Sold 2/1/14-4/30/14: $3,017,000gr. / 1,543,383sh. = $1.95/sh.
• Sold 5/1/14-7/31/14: $425,000gr. / 226,700sh. = $1.92/sh.
• Sold 8/1/14-10/31/14: $3,891,000gr. / 2,494,835sh. = $1.56/sh.
• Sold 11/1/14-1/31/15: $1,878,000gr. / 1,261,825sh. = $1.49/sh.
*Total Raised via MLV Dec’12 ATM Sales thru 10-31-2014:
. . .Before 7-10-17 1:7RS: $75,000,000gr. / 46,831,404 = $1.60sh.
. . .After 7-10-17 1:7RS: $75,000,000gr. / 6,690,200 = $1.21sh.
V. MLV 6-2014: “Jun’14 AMI Agreement – up to $25mm” http://www.mlvco.com
Form 424B5 filed 6-13-15: http://tinyurl.com/ycxje6pj
• Sold 11/1/14-1/31/15: $1,193,000gr. / 869,504sh. = $1.43/sh.
• Sold 2/1/15-3/12/15: $6,204,000gr. / 4,354,954sh. = $1.44/sh.
• Sold 3/13/15-4/30/15: $6,147,000gr. / 4,457,299sh. = $1.38/sh.
• Sold 5/1/15-7/14/15: $8,896,000gr. / 6,534,400sh. = $1.36/sh.
• Sold 7/15/15-7/31/15: $1,270,000gr. / 1,003,830sh. = $1.27/sh.
• Sold 8/1/15-9/9/15: $1,290,000gr. / 1,091,508sh. = $1.18/sh.
*Total Raised via MLV Jun’14 ATM Sales thru 9-9-2015:
. . .Before 7-10-17 1:7RS: $25,000,000gr. / 18,311,495 = $1.37/sh.
. . .After 7-10-17 1:7RS: $25,000,000gr. / 2,615,928 = $9.56/sh.
VI. MLV 8-2015: “Aug’15 AMI Agreement – up to $30mm” http://www.mlvco.com
Form 424B5 filed 8-7-15: http://tinyurl.com/oc53ugn
• Sold 8/7/15-9/9/15: $892,000gr. / 1,091,000sh. = $1.18/sh.
• Sold 9/10/15-10/31/15: $4,294,000gr. / 4,059,478sh. = $1.06/sh.
• Sold 11/1/15-12/10/15: $2,261,000gr. / 1,939,413sh. = $1.17/sh.
• Sold 12/11/15-1/31/16: *NO ATM SALES*, per 1-31-16 10Q iss. 3-9-16
• Sold 2/2/16-4/30/16: *NO ATM SALES*, per 4-30-16 10Q iss. 7-14-16
• Sold 5/1/16-7/14/16: $937,000gr. / 1,876,918sh. = $.50/sh.
• Sold 7/15/16-9/8/16: *NO ATM SALES*, per 7-31-16 10Q iss. 9-8-16
• Sold 9/9/16-10/31/16: $2,513,000gr. / 6,432,439sh. = $.39/sh.
• Sold 11/1/16-12/12/16: $1,174,000gr. / 3,788,346sh. = $.31/sh.
• Sold 12/13/16-1/31/17: $3,404,000gr. / 11,069,646sh. = $.31/sh.
• Sold 2/1/17-3/13/17: $7,335,000gr. / 15,308,300sh. = $.48/sh.
• Sold 3/14/17-4/30/17: $2,883,000gr. / 4,486,182 = $.64/sh.
• Sold 5/1/17-6/30/17: $4,307,000gr. / 7,358,806 = $0.59/sh.
. . .Before 7-10-17 1:7RS: $30,000,000gr. / 57,072,288 = $.53/sh.
. . .After 7-10-17 1:7RS: $30,000,000gr. / 8,153,184 = $3.68/sh.
VII. NOBLE 8-2015: “Aug’15 Eq.Dist. Agreement – up to $20mm” http://www.noblelsp.com
Form 424B5 filed 8-7-15: http://tinyurl.com/yazonjyw
• Sold 11/1/15-12/10/16: $2,371,000gr. / 1,925,844sh. = $1.23/sh.
• Sold 12/11/15-1/31/16: $2,857,000gr. / 2,529,434sh. = $1.13/sh.
• Sold 2/1/16-4/30/16: $1,741,000gr. / 4,017,010sh. = $.43/sh.
• Sold 5/1/16-7/14/16: $1,233,000gr. / 2,649,318sh. = $.47/sh.
• Sold 7/15/16-9/8/16: *NO ATM SALES*, per 7-31-16 10Q iss. 9-8-16
• Sold 9/9/16-10/31/16: $1,283,000gr. / 2,988,086sh. = $.43/sh.
• Sold 11/1/16-12/12/16: $496,000gr. / 1,587,909sh. = $.31/sh.
• Sold 12/13/16-1/31/17: $904,000gr. / 2,857,284sh. = $.32/sh.
• Sold 2/1/17-3/13/17: $6,006,000gr. / 11,273,296sh. = $.53/sh.
• Sold 3/14/17-4/30/17: $3,109,000gr. / 4,896,376sh. = $.63/sh.
. . .Before 7-10-17 1:7RS:$20,000,000gr. / 34,724,557 = $.58/sh.
. . .After 7-10-17 1:7RS:$20,000,000gr. / 4,960,651 = $4.03/sh.
TOTAL ALL A-T-M SALES – INCEPTION (3-2009) THRU 6-30-2017:
. . .Before 7-10-17 1:7RS: => $272,500,000gr. / 244,088,231sh. = $1.12/sh.
. . .After 7-10-17 1:7RS: => $272,500,000gr. / 34,869,747sh. = $7.81/sh.
= = = = = = = = = = = = = = = = = =
O/S WARRANTS & STOCK-OPTIONS A/O 7-31-2017 (10Q pgs. 13-14):
• WARRANTS: As of 7-31-17, warrants to purchase 39,040 shares at an exercise price of $17.29 were outstanding and are exercisable thru Aug30 2018. These warrants were issued in FY’13 in connection with the Aug.2012 [Oxford] loan agreement, which was paid in full Sept.2012.
• STOCK OPTIONS OUTSTANDING A/O 7-31-17: 4,022,136 shares at a wgt.avg. exercise price of $8.73.
- - - - - - - - - - - - - - - - -
Latest 10K 4-30-17 iss. 7-14-17 http://tinyurl.com/ycxu4l5n PR: http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=1033237 (Cash 4-30-17=$46.8mm)
Latest 10Q 7-31-17 iss. 9-11-17 http://tinyurl.com/ycbzp4zn PR: http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=1039958 (Cash 7-31-17=$37.3mm)
ALL SEC filings for PPHM: http://tinyurl.com/6d4jw8
10-13-16 ASM Voting Results: http://tinyurl.com/ycrrrb43
= = = = = = = = = = =PREFERRED STOCK:
2-5-14: PPHM Announces Public Offering of 10.5% Series E Convertible Preferred Stock http://tinyurl.com/lkxsna6
...2-11-14: PPHM Raises net $16.2mm selling 700k Preferred Shares with 10.5% div. at $25/sh, convertible to common at $3/sh http://tinyurl.com/jwmsnsk (8-K)
...6/14/14-7/14/13: PPHM Raises net $9.5mm selling 400k Preferred Shares with 10.5% div. at $25/sh, convertible to common at $3/sh http://tinyurl.com/mhva3k3 (4-30-14 10-K pg. F-34; $20mm gross remaining)
PREFERRED SHARES:
4-30-15 10K/p.F26: On 6-13-14, we entered into an At Market Issuance Sales Agreement with MLV, pursuant to which we may issue & sell shares of our Series E Preferred Stock through MLV, as agent, for gross proceeds of up to $30,000,000, in registered transactions from our Jan2014 Shelf. During FY’2015, we sold 799,764 shares of our Series E Preferred Stock at mkt prices for gross $19,205,000 before deducting commissions/costs of $1,002,000. As of 4-30-15, gross proceeds of up to $10,795,000 remained available under the Series E AMI Agreement.
NOTE: One of the holders of Preferred is KENNETH DART (EASTERN CAPITAL), who in a 2-13-15 SG14G ( http://tinyurl.com/k4nsfuu ) reported their 240,000sh. Preferred holdings as 2,000,000 common shares (SHARED VOTING POWER: 9,921,760,% OF CLASS REPRESENTED: 5.4%).
“which has a liquidation preference of $25.00/sh. and a conversion price of $3.00/sh.” 2,000,000 / 240,000 = 8.333
10Q: http://tinyurl.com/j2u2bjk
**7-31-16 10Q(iss. 9-8-16): 8/1/16-9/8/16, we sold 68,910sh. for gross=$1,601,000; a/o 9-8-16, $9,134,000 remained available.
**7-31-17 10Q(iss. 9-11-17): Preferred stock O/S at 7-31-17: 1,647,760
Known Upcoming Events, Large-Shareholders(35%), RONIN-PPHM HISTORY: updated 9-6-17 with PPHM announcing that Q1’FY18(q/e 7-31-17) 10Q/CC will be on Monday 9-11-17/after-hrs. Also, 9-9-17/ESMO’17 (SUNRISE Final Data) added to Known Events.
NOTE: RONIN/SWIM’s 8-29-17 PRELIM. Proxy Statement (14A) and PPHM’s 8-28-17 Amended 10-K were added previously – see below...
KNOWN UPCOMING:
Sep11/AfterHrs: FY'18Q1 (qe 7-31-17) Financials & Conf. Call http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=1039405
Sep8-12/ESMO’17(Madrid), PPHM Booth #257: Final SUNRISE Ph3 Data http://tinyurl.com/yb9kjutp
...Sep9 1:15pm Poster #1364P: “Final Clinical Results from SUNRISE: A Ph3 Trial of Bavi+Doce/Prev. Treated IIIb/IV NSCLC”. In an exploratory analysis of OS for pts who received subsequent ICI, mOS was not reached.
Sep25-28/Avid Booth #918: Informa’s BPI’17: BioProcess Intl. Conf. & Exhibition, Boston https://lifesciences.knect365.com/bioprocessinternational
Oct2/NCI Scientist Gregoire Altan-Bonnet(MSKCC ties), AACR’s Tumor Immunotherapy Conf., Boston http://tinyurl.com/y74v76go
...“Long-Lived Disruption of Inflammation Stems from the Catch-and-Release of Cytokines Mediated by Surface Phosphatidylserine in Tumors”
~Oct12: Peregrine's Annual Shareholder’s Meeting (2016 attendee reports: http://tinyurl.com/jx7ouay )
Dec11-15/Avid Booth #311: KNect365’s Antibody Eng. & Therapeutics Conf., SanDiego https://lifesciences.knect365.com/antibody-engineering-therapeutics
~Dec11: FY'18Q2 (qe 10-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Jan20-22 2018: Phacilitate’s Immunotherapy World Forum, Miami http://www.immunotherapyforum.com
...Jan18 12:30-12:45, Joe Shan(VP/Reg+Clin): “Turning up the Heat: PS-Targeting Antibodies Modulate the Tumor Microenvironment & Enhance Checkpoint Blockade”
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
7-20-17: Large Ownership Summary(34.8%), RONIN Letters/PPHM Comments
Large Ownership now ~15.8mm shares, 34.9% of ~45.1mm O/S. (Ronin+SW/Stafford+White, Eastern Cap./K.Dart, Institutions incl. Tappan’s 8-14-17/13G)
#1: 10-30-15: Kenneth Dart (Eastern Capital) acquires 9.5% stake (4,300,992sh.) in PPHM http://tinyurl.com/y95yskck
...3,777,183 COMMON – 8.4% of 45,096,081 common O/S at 8-25-17 (total beneficial=4,300,992 if Pref. conv. x1.19 to Common, 9.5%)
...440,000 PREFERRED – 26.7% of 1,647,760 preferred O/S at 1-31-17
#2: 7-14-17/13D: Group Ronin Trading/SWInvest (John Stafford III+Stephen White) acquires 8.8% stake (3,979,699sh.) in PPHM http://tinyurl.com/y7ezqvm9
...3,828,391 COMMON – 8.5% of 45,096,081 common O/S at 8-25-17 (total beneficial=3,979,699 if Pref. conv. x1.19 to Common, 8.8%)
...127,099 PREFERRED – 7.7% of 1,647,760 preferred O/S at 1-31-17
NOTE: ALL historical common #’s adjusted for the 1:7 R/S eff. 7-10-17.
RONIN/SW 13D SUMMARY:
13D TransDates COMMON-CHG PREF-CHG ENDING-COMMON ENDING-PREF.
3-2-17 1/20/17-3/1/17 +2,947,425 +51,364 2,947,425 51,364 http://tinyurl.com/jr42u23
3-10-17 3/2/17-3/9/17 +433,509 +25,661 3,380,934 77,025 http://tinyurl.com/ydxra96u
4-17-17 3/28/17-4/10/17 0 +23,334 3,380,934 100,359 http://tinyurl.com/lanjddc
5-19-17 5/1/17-5/17/17 0 +23,140 3,380,934 123,499 http://tinyurl.com/mgnn92x
6-20-17 3/10/17-6/16/17 +378,170 0 3,759,105 123,499 http://tinyurl.com/y76q5rqu
6-29-17 6/21/17 +7,143 0 3,766,248 123,499 http://tinyurl.com/y9sp8bfv
7-14-17 6/29/17-7/7/17 +34,891 +3,600 3,801,139 127,099 http://tinyurl.com/ybra4s69
8-29-17 8/4/17-8/15/17 +27,252 0 3,828,391 127,099 http://tinyurl.com/yay55u3p (14A)
SPLITOUT 13D GROUP into Ronin(John Stafford III) and SW-Partners(Stephen White):
Ronin Trading (Stafford) 3,173,391 115,299
SW-Partners (White) 655,000 11,800
See Ronin/SWIM 13D’s Details Below.
- - - - - - - - - - - - - - -
Plus, INSTITUTIONS a/o 6-30-17: 7,476,857sh. = 16.6% <=incl. Tappan’s 8-14-17/13G,
...and KennedyCAP corrected 9,758,459=>1,394,066(Nasdaq R/S error)
...15,198,818 +(1,394,066-9,758,459) + (2,298,684-1,656,252) = 7,476,857
http://www.nasdaq.com/symbol/pphm/institutional-holdings
TOP7:
Tappan St. Partners 2,298,684 +1,384,380 <=per 8-14-17/13G(see below**)
Kennedy Capital Mgt. 1,394,066 +146,842
Vanguard Group 1,029,755 +146,791
Blackrock (Larry Fink) 806,022 -49,433
Renaissance Technologies 481,160 +41,487
Geode Capital Mgt. 225,679 +20,319
Bandera Partners 203,004 New
**8-14-17/13G: Tappan Street (Prasad Phatak) http://tinyurl.com/ybgqp9uq
2 Funds + P.Phatak’s personal shares:
...Partners LLC, Tappan St. Fund L.P. 1,540,000
...Tappan St. Partners Ideas Fund L.P. 691,577
...Prasad Phatak (Principle Owner) 67,107 Total TAPPAN: 2,298,684 (5.1%)
Note: Tappan Inst. Holdings a/o 3-31-17 was: 914,304, 1,656,252 at 6-30-17.
9-9-17/ESMO’17: Final SUNRISE Ph3 Data, Poster #1364P
Sept8-12 2017: “42nd ESMO European Cancer Congress”, Madrid
http://www.esmo.org/Conferences/ESMO-2017-Congress
ESMO = European Society for Medical Oncology
ECCO = European CanCer Organization
Pgm: http://www.esmo.org/Conferences/ESMO-2017-Congress/Programme
PEREGRINE EXHIBITING: BOOTH #257
9-9-17 1:15-2:15pm Poster #1364P:
“Final Clinical Results from SUNRISE: A Phase III Multicenter Trial of Bavituximab+Docetaxel in Patients with Prev. Treated Stage IIIb/IV nonsquamous NSCLC”
R. Palmero (Barcelona, Spain) P. Bidoli (Italy) I.M. Bondarenko (Ukraine) M. Boyer (Australia) P. Germonpre (Belgium) D. Ghizdavescu (Romania) A. Kotsakis (Greece) H. Lena (France) G. Losonczy (Hungary) K. Park (Korea) M. Reck (Germany) W. Su (Taiwan) N. Kallinteris (Tustin) M. Tang (Tustin) J. Lai (Tustin) J. Shan (Tustin) D.R. Spigel (Nashville TN)
ABSTRACT: https://cslide.ctimeetingtech.com/library/esmo/browse/search/5uD#2Bb5o
BACKGROUND:
Exposed phosphatidylserine (PS) in the tumor microenvironment is highly immunosuppressive. Bavituximab targets PS and repolarizes M2 macrophages to M1 resulting in production of pro-inflammatory cytokines such as IFN-y and IL-12, maturation of dendritic cells, and tumor specific cytotoxic T lymphocyte immunity. In a prior blinded Phase II trial in 2nd-line nonsquamous NSCLC, bavituximab+docetaxel was well-tolerated and demonstrated 60% improvement (11.7 vs 7.3mos.) in mOS (HR=.66; P=.11) compared to control. [2-19-16/Clin-Lung-Cancer-Jrnl: Ph2 Final Data, Dr. David Gerber etal http://tinyurl.com/z5a7fwu ]
METHODS:
597 patients with Stage IIIb/IV nonsquamous NSCLC that progressed on platinum-doublet chemotherapy were randomized 1:1 to receive up to 6 21-day cycles of docetaxel in combination with weekly 3mg/kg bavituximab (B+D) or placebo (D) until progression or toxicity. The primary endpoint was OS. Secondary endpoints included PFS, ORR, and safety.
RESULTS:
With 12mos. follow-up from the last patient randomized and ~85% of the targeted OS events reached, mOS was 10.5mos. (95% CI, 8.4-11.9) among 297 patients in B+D and 10.9mos. (95% CI, 9.2-12.1) among 300 patients in D (HR, 1.06; P=.533). PFS was 4.2mos. (95% CI, 3.9-4.6) in B+D and 4.1mos. (95% CI, 3.2-4.8) in D (HR, 1.02; P=.876). The ORR was 15% in B+D vs. 11% in D (odds ratio, 0.7; P=.15). The safety profile was similar between groups. Grade 3 or higher adverse events occurred in 68% of patients in B+D and 60% in D. In an exploratory analysis of OS for patients who received subsequent immune checkpoint inhibitors (ICI), the mOS was not reached (95% CI, 15.2-NA) in B+D (n=46) and 12.6mos. (95% CI, 10.4-17.8) in D (n=47) (HR=.46; P=.006).
CONCLUSIONS:
The combination of B+D was well-tolerated though no OS difference was observed compared to D alone in the ITT population of prev. treated nonsquamous NSCLC. An exploratory analysis of patients who received subsequent ICI found significantly longer OS in patients who received prior B+D than those who received D and support further clinical investigation of B+ICI in NSCLC.
= = = = = = = = = = = = = = = = =
Sunrise Biomarker studies - 4 announced thru ASCO'17, see http://tinyurl.com/ydhf6tfx
......#1 10-10-16/ESMO’16: B2GPI/200-240(30%pts) StatSig MOS 7.7=>13.2mos. http://tinyurl.com/hp73njt
......#2 12-7-16/WCLC’16(IASLC): “Complement & IL-10 Pathways: Pts Benefiting from Bavi+Doce” <=Presentation CANCELLED/”Anal.Not.Finished(IR)” http://tinyurl.com/z8cq8vx
......#3 4-3-17/AACR'17: "IFN-y Analysis In Blood & Tissue as a Potential Prognostic and/or Predictive Biomarker” See: http://tinyurl.com/ktzr782
......#4 6-3-17/ASCO'17: "Prelim. Correlative Analysis of PD-L1 Expression from the Sunrise Study” See ASCO'17: http://tinyurl.com/y93upatl
Note: PPHM's Amended/10K & Ronin's Prelim-Proxy added.
Known Upcoming Events, Large-Shareholders(35%), RONIN-PPHM HISTORY: updated 8-29-17 with RONIN/SWIM’s PRELIM. Proxy (14A), filed 8-29-17 [http://tinyurl.com/yay55u3p ], which states, “We are seeking your support for the election of our 3 BOD nominees at the PPHM 2017 ASM: Gregory P. Sargen, Brian W. Scanlan, Saiid Zarrabian.”, as well as approval to “To hold a non-binding advisory vote on the compensation of the Company’s named executive officers”. This 14A (pgs.5-9) also lists a 35-pt. chronology of events (1-17-17 thru 8-14-17) leading up to this proxy solicitation. Also, pgs. I1-4 lists all Ronin/SW PPHM stock transactions, since 12-15-16 – it shows 2 new purchases of Common since the last 13D: SWIM/SWInvest(S.White): 8-4-17/16,026 and 8-15-17/11,226. (+27,252 total). This results in Ronin/SW Group total beneficial ownership moving from 3,952,446 to 3,979,699 (8.8% of 45,096,081 outstanding as of 8-25-17).
NOTE:
PPHM’s AMENDED 10-K was filed 8-28-17 (http://tinyurl.com/yb5jq7vc ) - see below for more info.
KNOWN UPCOMING: ~Sep7: FY'18Q1 (qe 7-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Sep8-12: 42nd ESMO Eur. Cancer Congress”, Madrid http://www.esmo.org/Conferences/ESMO-2017-Congress
...Peregrine Exhibiting: Booth #257
Sep25-28/Avid Booth #918: Informa’s BPI’17: BioProcess Intl. Conf. & Exhibition, Boston https://lifesciences.knect365.com/bioprocessinternational
Oct2/NCI Scientist Gregoire Altan-Bonnet(MSKCC ties), AACR’s Tumor Immunotherapy Conf., Boston http://tinyurl.com/y74v76go
...“Long-Lived Disruption of Inflammation Stems from the Catch-and-Release of Cytokines Mediated by Surface Phosphatidylserine in Tumors”
~Oct12: Peregrine's Annual Shareholder’s Meeting (2016 attendee reports: http://tinyurl.com/jx7ouay )
Dec11-15/Avid Booth #311: KNect365’s Antibody Eng. & Therapeutics Conf., SanDiego https://lifesciences.knect365.com/antibody-engineering-therapeutics
~Dec11: FY'18Q2 (qe 10-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Jan20-22 2018: Phacilitate’s Immunotherapy World Forum, Miami http://www.immunotherapyforum.com
...Jan18 12:30-12:45, Joe Shan(VP/Reg+Clin): “Turning up the Heat: PS-Targeting Antibodies Modulate the Tumor Microenvironment & Enhance Checkpoint Blockade”
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
7-20-17: Large Ownership Summary(34.8%), RONIN Letters/PPHM Comments
Large Ownership now ~15.8mm shares, 34.9% of ~45.1mm O/S. (Ronin+SW/Stafford+White, Eastern Cap./K.Dart, Institutions incl. Tappan’s 8-14-17/13G)
#1: 10-30-15: Kenneth Dart (Eastern Capital) acquires 9.5% stake (4,300,992sh.) in PPHM http://tinyurl.com/y95yskck
...3,777,183 COMMON – 8.4% of 45,096,081 common O/S at 8-25-17 (total beneficial=4,300,992 if Pref. conv. x1.19 to Common, 9.5%)
...440,000 PREFERRED – 26.7% of 1,647,760 preferred O/S at 1-31-17
#2: 7-14-17/13D: Group Ronin Trading/SWInvest (John Stafford III+Stephen White) acquires 8.8% stake (3,979,699sh.) in PPHM http://tinyurl.com/y7ezqvm9
...3,838,391 COMMON – 8.5% of 45,096,081 common O/S at 8-25-17 (total beneficial=3,979,699 if Pref. conv. x1.19 to Common, 8.8%)
...127,099 PREFERRED – 7.7% of 1,647,760 preferred O/S at 1-31-17
NOTE: ALL historical common #’s adjusted for the 1:7 R/S eff. 7-10-17.
RONIN/SW 13D SUMMARY:
13D TransDates COMMON-CHG PREF-CHG ENDING-COMMON ENDING-PREF.
3-2-17 1/20/17-3/1/17 +2,947,425 +51,364 2,947,425 51,364 http://tinyurl.com/jr42u23
3-10-17 3/2/17-3/9/17 +433,509 +25,661 3,380,934 77,025 http://tinyurl.com/ydxra96u
4-17-17 3/28/17-4/10/17 0 +23,334 3,380,934 100,359 http://tinyurl.com/lanjddc
5-19-17 5/1/17-5/17/17 0 +23,140 3,380,934 123,499 http://tinyurl.com/mgnn92x
6-20-17 3/10/17-6/16/17 +378,170 0 3,759,105 123,499 http://tinyurl.com/y76q5rqu
6-29-17 6/21/17 +7,143 0 3,766,248 123,499 http://tinyurl.com/y9sp8bfv
7-14-17 6/29/17-7/7/17 +34,891 +3,600 3,801,139 127,099 http://tinyurl.com/ybra4s69
8-29-17 8/4/17-8/15/17 +27,252 0 3,838,391 127,099 http://tinyurl.com/yay55u3p (14A)
SPLITOUT 13D GROUP into Ronin(John Stafford III) and SW-Partners(Stephen White):
Ronin Trading (Stafford) 3,173,391 115,299
SW-Partners (White) 655,000 11,800
See Ronin/SWIM 13D’s Details Below.
- - - - - - - - - - - - - - -
Plus, INSTITUTIONS a/o 6-30-17: 7,476,857sh. = 16.6% <=incl. Tappan’s 8-14-17/13G,
...and KennedyCAP corrected 9,758,459=>1,394,066(Nasdaq R/S error)
...15,198,818 +(1,394,066-9,758,459) + (2,298,684-1,656,252) = 7,455,228
http://www.nasdaq.com/symbol/pphm/institutional-holdings
TOP7:
Tappan St. Partners 2,298,684 +1,384,380 <=per 8-14-17/13G(see below**)
Kennedy Capital Mgt. 1,394,066 +146,842
Vanguard Group 1,029,755 +146,791
Blackrock (Larry Fink) 806,022 -49,433
Renaissance Technologies 481,160 +41,487
Geode Capital Mgt. 225,679 +20,319
Bandera Partners 203,004 New
**8-14-17/13G: Tappan Street (Prasad Phatak) http://tinyurl.com/ybgqp9uq
2 Funds + P.Phatak’s personal shares:
...Partners LLC, Tappan St. Fund L.P. 1,540,000
...Tappan St. Partners Ideas Fund L.P. 691,577
...Prasad Phatak (Principle Owner) 67,107 Total TAPPAN: 2,298,684 (5.1%)
Note: Tappan Inst. Holdings a/o 3-31-17 was: 914,304, 1,656,252 at 6-30-17.
The 2nd (6-22-17) Exosomes article by Dr.Schroit was not PR’d nor mentioned in the 7-14-17 PR/CC.
...Known POC Data Summary (see below):
1-22-17/OncoTarget: Ovarian – senior author Alan Schroit (UTSW/PPHM SAB)
6-22-17/Nature(BJC): Breast & Pancreatic – senior author Alan Schroit (UTSW/PPHM SAB) *Using Betabody KL15C*
Here’s the latest that we know:
7-14-17/CEO Steve King: “On the R&D side, we are pleased to report that the company continues to make progress with its PS-targeting Exosome Diagnostic Technology that is designed to detect & monitor cancer. Our scientists have successfully optimized the assay and we are currently preparing to generate addl. Data, testing the diagnostic with an expanded set of human samples. Such data will be important to partnering discussions and we’ll keep you posted on progress." http://tinyurl.com/yb4wulvu
See: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=133023785
CP, 2 major errors there: #1, Tappan now owns 2,298,684, 5.1%. #2, the Nasdaq Inst.Holdings page has an ERROR on KENNEDY-Cap – they’re showing 9,758,459, but it s/b 1,394,066 because they failed to apply the 7-10-17 1:7 RS. This error has been reported to them.
It’s all right here:
Large Ownership now ~15.7mm shares, 34.9% of 45mm O/S. (Ronin+SW/Stafford+White, Eastern Cap./K.Dart, Institutions incl. Tappan’s 8-14-17/13G)
#1: 10-30-15: Kenneth Dart (Eastern Capital) acquires 9.6% stake (4,300,992sh.) in PPHM http://tinyurl.com/y95yskck
...3,777,183 COMMON – 8.4% of 45,069,188 common O/S at 7-10-17 (total beneficial=4,300,992 if Pref. conv. x1.19 to Common, 9.6%)
...440,000 PREFERRED – 26.7% of 1,647,760 preferred O/S at 1-31-17
#2: 7-14-17/13D: Group Ronin Trading/SWInvest (John Stafford III+Stephen White) acquires 8.8% stake (3,952,446sh.) in PPHM http://tinyurl.com/y7ezqvm9
...3,801,139 COMMON – 8.4% of 45,069,188 common O/S at 7-10-17 (total beneficial=3,952,446 if Pref. conv. x1.19 to Common, 8.8%)
...127,099 PREFERRED – 7.7% of 1,647,760 preferred O/S at 1-31-17
NOTE: ALL historical common #’s adjusted for the 1:7 R/S eff. 7-10-17.
RONIN/SW 13D SUMMARY:
13D TransDates COMMON-CHG PREF-CHG ENDING-COMMON ENDING-PREF.
3-2-17 1/20/17-3/1/17 +2,947,425 +51,364 2,947,425 51,364 http://tinyurl.com/jr42u23
3-10-17 3/2/17-3/9/17 +433,509 +25,661 3,380,934 77,025 http://tinyurl.com/ydxra96u
4-17-17 3/28/17-4/10/17 0 +23,334 3,380,934 100,359 http://tinyurl.com/lanjddc
5-19-17 5/1/17-5/17/17 0 +23,140 3,380,934 123,499 http://tinyurl.com/mgnn92x
6-20-17 3/10/17-6/16/17 +378,170 0 3,759,105 123,499 http://tinyurl.com/y76q5rqu
6-29-17 6/21/17 +7,143 0 3,766,248 123,499 http://tinyurl.com/y9sp8bfv
7-14-17 6/29/17-7/7/17 +34,891 +3,600 3,801,139 127,099 http://tinyurl.com/ybra4s69
SPLITOUT 13D GROUP into Ronin(John Stafford III) and SW-Partners(Stephen White):
Ronin Trading (Stafford) 3,173,391 115,299
SW-Partners (White) 627,748 11,800
See Ronin/SWIM 13D’s Details Below.
- - - - - - - - - - - - - - -
Plus, INSTITUTIONS a/o 6-30-17: 7,462,716sh. = 16.5% <=incl. Tappan’s 8-14-17/13G,
...and KennedyCAP corrected 9,758,459=>1,394,066(Nasdaq R/S error)
...15,184,677 +(1,394,066-9,758,459) + (2,298,684-1,656,252) = 7,462,716
http://www.nasdaq.com/symbol/pphm/institutional-holdings
TOP7:
Tappan St. Partners 1,656,252 +741,948 <=2,298,684 per 8-14-17/13G(see below**)
Kennedy Capital Mgt. 1,394,066 +146,842
Vanguard Group 1,029,755 +146,791
Blackrock (Larry Fink) 806,022 -49,433
Renaissance Technologies 481,160 +41,487
Geode Capital Mgt. 225,679 +20,319
Bandera Partners 203,004 New
**8-14-17/13G: Tappan Street (Prasad Phatak) http://tinyurl.com/ybgqp9uq
2 Funds + P.Phatak’s personal shares:
...Partners LLC, Tappan St. Fund L.P. 1,540,000
...Tappan St. Partners Ideas Fund L.P. 691,577
...Prasad Phatak (Principle Owner) 67,107 Total TAPPAN: 2,298,684 (5.1%)
Note: Tappan Inst. Holdings a/o 3-31-17 was: 914,304.
Known Upcoming Events, Large-Shareholders(35%), RONIN-PPHM HISTORY: updated 8-15-17 with Ronin/SWIM’s PR, “Responding to Recent Announcements by Peregrine”, a 8-14-17 Amended 13G for Tappan St. Partners (Prasad Phatak, Principle Owner, 2 Funds+personal: 2,298,684 total = 5.1% of 45mm O/S), and Inst. Holdings totals updated to 6-30-17...
KNOWN UPCOMING:
Aug15-16: CBI’s MES 2017 (Mfg. Execution Systems), Orlando http://tinyurl.com/ya4twmbj
...Aug16/8:45am: Mehron Mirian (SeniorMgr./QA Validation), "MES AUDIT DEEP DIVE Computerized System Audit"
Aug21-25/Avid Booth #403: CHI's 9th Annual BioProcessing Summit, Boston http://www.bioprocessingsummit.com
~Sep7: FY'18Q1 (qe 7-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Sep8-12: 42nd ESMO Eur. Cancer Congress”, Madrid http://www.esmo.org/Conferences/ESMO-2017-Congress
...Peregrine Exhibiting: Booth #257
Sep25-28/Avid Booth #918: Informa’s BPI’17: BioProcess Intl. Conf. & Exhibition, Boston https://lifesciences.knect365.com/bioprocessinternational
Oct2/NCI Scientist Gregoire Altan-Bonnet(MSKCC ties), AACR’s Tumor Immunotherapy Conf., Boston http://tinyurl.com/y74v76go
...“Long-Lived Disruption of Inflammation Stems from the Catch-and-Release of Cytokines Mediated by Surface Phosphatidylserine in Tumors”
~Oct12: Peregrine's Annual Shareholder’s Meeting (2016 attendee reports: http://tinyurl.com/jx7ouay )
Dec11-15/Avid Booth #311: KNect365’s Antibody Eng. & Therapeutics Conf., SanDiego https://lifesciences.knect365.com/antibody-engineering-therapeutics
~Dec11: FY'18Q2 (qe 10-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Jan20-22 2018: Phacilitate’s Immunotherapy World Forum, Miami http://www.immunotherapyforum.com
...Jan18 12:30-12:45, Joe Shan(VP/Reg+Clin): “Turning up the Heat: PS-Targeting Antibodies Modulate the Tumor Microenvironment & Enhance Checkpoint Blockade”
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
7-20-17: Large Ownership Summary(35%), RONIN Letters/PPHM Comments
Large Ownership now ~15.7mm shares, 34.9% of 45mm O/S. (Ronin+SW/Stafford+White, Eastern Cap./K.Dart, Institutions incl. Tappan’s 8-14-17/13G)
#1: 10-30-15: Kenneth Dart (Eastern Capital) acquires 9.6% stake (4,300,992sh.) in PPHM http://tinyurl.com/y95yskck
...3,777,183 COMMON – 8.4% of 45,069,188 common O/S at 7-10-17 (total beneficial=4,300,992 if Pref. conv. x1.19 to Common, 9.6%)
...440,000 PREFERRED – 26.7% of 1,647,760 preferred O/S at 1-31-17
#2: 7-14-17/13D: Group Ronin Trading/SWInvest (John Stafford III+Stephen White) acquires 8.8% stake (3,952,446sh.) in PPHM http://tinyurl.com/y7ezqvm9
...3,801,139 COMMON – 8.4% of 45,069,188 common O/S at 7-10-17 (total beneficial=3,952,446 if Pref. conv. x1.19 to Common, 8.8%)
...127,099 PREFERRED – 7.7% of 1,647,760 preferred O/S at 1-31-17
NOTE: ALL historical common #’s adjusted for the 1:7 R/S eff. 7-10-17.
RONIN/SW 13D SUMMARY:
13D TransDates COMMON-CHG PREF-CHG ENDING-COMMON ENDING-PREF.
3-2-17 1/20/17-3/1/17 +2,947,425 +51,364 2,947,425 51,364 http://tinyurl.com/jr42u23
3-10-17 3/2/17-3/9/17 +433,509 +25,661 3,380,934 77,025 http://tinyurl.com/ydxra96u
4-17-17 3/28/17-4/10/17 0 +23,334 3,380,934 100,359 http://tinyurl.com/lanjddc
5-19-17 5/1/17-5/17/17 0 +23,140 3,380,934 123,499 http://tinyurl.com/mgnn92x
6-20-17 3/10/17-6/16/17 +378,170 0 3,759,105 123,499 http://tinyurl.com/y76q5rqu
6-29-17 6/21/17 +7,143 0 3,766,248 123,499 http://tinyurl.com/y9sp8bfv
7-14-17 6/29/17-7/7/17 +34,891 +3,600 3,801,139 127,099 http://tinyurl.com/ybra4s69
SPLITOUT 13D GROUP into Ronin(John Stafford III) and SW-Partners(Stephen White):
Ronin Trading (Stafford) 3,173,391 115,299
SW-Partners (White) 627,748 11,800
See Ronin/SWIM 13D’s Details Below.
- - - - - - - - - - - - - - -
Plus, INSTITUTIONS a/o 6-30-17: 7,462,716sh. = 16.5% <=incl. Tappan’s 8-14-17/13G,
...and KennedyCAP corrected 9,758,459=>1,394,066(Nasdaq R/S error)
...15,184,677 +(1,394,066-9,758,459) + (2,298,684-1,656,252) = 7,462,716
http://www.nasdaq.com/symbol/pphm/institutional-holdings
TOP7:
Tappan St. Partners 1,656,252 +741,948 <=2,298,684 per 8-14-17/13G(see below**)
Kennedy Capital Mgt. 1,394,066 +146,842
Vanguard Group 1,029,755 +146,791
Blackrock (Larry Fink) 806,022 -49,433
Renaissance Technologies 481,160 +41,487
Geode Capital Mgt. 225,679 +20,319
Bandera Partners 203,004 New
**8-14-17/13G: Tappan Street (Prasad Phatak) http://tinyurl.com/ybgqp9uq
2 Funds + P.Phatak’s personal shares:
...Partners LLC, Tappan St. Fund L.P. 1,540,000
...Tappan St. Partners Ideas Fund L.P. 691,577
...Prasad Phatak (Principle Owner) 67,107 Total TAPPAN: 2,298,684 (5.1%)
Note: Tappan Inst. Holdings a/o 3-31-17 was: 914,304.
Known Upcoming Events, Large-Shareholders(35%), RONIN-PPHM HISTORY: updated 8-14-17 with Ronin/SWIM’s PR, “Responding to Recent Announcements by Peregrine”, also Inst. Holdings totals updated to 6-30-17 (~50% at this point)...
KNOWN UPCOMING:
Aug15-16: CBI’s MES 2017 (Mfg. Execution Systems), Orlando http://tinyurl.com/ya4twmbj
...Aug16/8:45am: Mehron Mirian (SeniorMgr./QA Validation), "MES AUDIT DEEP DIVE Computerized System Audit"
Aug21-25/Avid Booth #403: CHI's 9th Annual BioProcessing Summit, Boston http://www.bioprocessingsummit.com
~Sep7: FY'18Q1 (qe 7-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Sep8-12: 42nd ESMO Eur. Cancer Congress”, Madrid http://www.esmo.org/Conferences/ESMO-2017-Congress
...Peregrine Exhibiting: Booth #257
Sep25-28/Avid Booth #918: Informa’s BPI’17: BioProcess Intl. Conf. & Exhibition, Boston https://lifesciences.knect365.com/bioprocessinternational
Oct2/NCI Scientist Gregoire Altan-Bonnet(MSKCC ties), AACR’s Tumor Immunotherapy Conf., Boston http://tinyurl.com/y74v76go
...“Long-Lived Disruption of Inflammation Stems from the Catch-and-Release of Cytokines Mediated by Surface Phosphatidylserine in Tumors”
~Oct12: Peregrine's Annual Shareholder’s Meeting (2016 attendee reports: http://tinyurl.com/jx7ouay )
Dec11-15/Avid Booth #311: KNect365’s Antibody Eng. & Therapeutics Conf., SanDiego https://lifesciences.knect365.com/antibody-engineering-therapeutics
~Dec11: FY'18Q2 (qe 10-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Jan20-22 2018: Phacilitate’s Immunotherapy World Forum, Miami http://www.immunotherapyforum.com
...Jan18 12:30-12:45, Joe Shan(VP/Reg+Clin): “Turning up the Heat: PS-Targeting Antibodies Modulate the Tumor Microenvironment & Enhance Checkpoint Blockade”
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
7-20-17: Large Ownership Summary(35%), RONIN Letters/PPHM Comments
Large Ownership now ~15.7mm shares, 34.9% of 45mm O/S. (Ronin+SW/Stafford+White, Eastern Cap./K.Dart, Institutions)
#1: 10-30-15: Kenneth Dart (Eastern Capital) acquires 9.6% stake (4,300,992sh.) in PPHM http://tinyurl.com/y95yskck
...3,777,183 COMMON – 8.4% of 45,069,188 common O/S at 7-10-17 (total beneficial=4,300,992 if Pref. conv. x1.19 to Common, 9.6%)
...440,000 PREFERRED – 26.7% of 1,647,760 preferred O/S at 1-31-17
#2: 7-14-17/13D: Group Ronin Trading/SWInvest (John Stafford III+Stephen White) acquires 8.8% stake (3,952,446sh.) in PPHM http://tinyurl.com/y7ezqvm9
...3,801,139 COMMON – 8.4% of 45,069,188 common O/S at 7-10-17 (total beneficial=3,952,446 if Pref. conv. x1.19 to Common, 8.8%)
...127,099 PREFERRED – 7.7% of 1,647,760 preferred O/S at 1-31-17
NOTE: ALL historical common #’s adjusted for the 1:7 R/S eff. 7-10-17.
RONIN/SW 13D SUMMARY:
13D TransDates COMMON-CHG PREF-CHG ENDING-COMMON ENDING-PREF.
3-2-17 1/20/17-3/1/17 +2,947,425 +51,364 2,947,425 51,364 http://tinyurl.com/jr42u23
3-10-17 3/2/17-3/9/17 +433,509 +25,661 3,380,934 77,025 http://tinyurl.com/ydxra96u
4-17-17 3/28/17-4/10/17 0 +23,334 3,380,934 100,359 http://tinyurl.com/lanjddc
5-19-17 5/1/17-5/17/17 0 +23,140 3,380,934 123,499 http://tinyurl.com/mgnn92x
6-20-17 3/10/17-6/16/17 +378,170 0 3,759,105 123,499 http://tinyurl.com/y76q5rqu
6-29-17 6/21/17 +7,143 0 3,766,248 123,499 http://tinyurl.com/y9sp8bfv
7-14-17 6/29/17-7/7/17 +34,891 +3,600 3,801,139 127,099 http://tinyurl.com/ybra4s69
SPLITOUT 13D GROUP into Ronin(John Stafford III) and SW-Partners(Stephen White):
Ronin Trading (Stafford) 3,173,391 115,299
SW-Partners (White) 627,748 11,800
See 13D Details Below.
- - - - - - - - - - - - - - -
Plus, INSTITUTIONS a/o 6-30-17**: 7,455,687sh. = 16.5% <=incl. Tappan 7-20-2017 ADD
http://www.nasdaq.com/symbol/pphm/institutional-holdings
**Note: Approx. 50% updated with 6-30-17 figures, the rest still 3-31-17...
TOP7:
Tappan Street Partners 2,298,684 +1,384,380 <=7-20-17/13G: Tappan adds +1,384,380 http://tinyurl.com/y94egwwk
Kennedy Capital Mgt. 1,394,066 +146,842
Vanguard Group 1,029,755 +146,791
Blackrock (Larry Fink CEO) 806,022 -49,433
Renaissance Technologies 481,160 +41,487
Geode Capital Mgt. 205,360 +49,260 <=Sill a/o 3-31-17
Bandera Partners 203,004 New
Known Upcoming Events, Large-Shareholders(34%), RONIN-PPHM HISTORY: updated 8-11-17 with PPHM’s PR, “Peregrine Announces Measures to Reduce Costs, Facilitate Profitability, and Strengthen its Operations (20% reduction of workforce, 300=>240)”...
KNOWN UPCOMING:
Jul27: Final Settlement Hearing for 2013 Shareholder Derivative CA Lawsuit vs. BOD http://tinyurl.com/y982h3rt
Aug15-16: CBI’s MES 2017 (Mfg. Execution Systems), Orlando http://tinyurl.com/ya4twmbj
...Aug16/8:45am: Mehron Mirian (SeniorMgr./QA Validation), "MES AUDIT DEEP DIVE Computerized System Audit"
Aug21-25/Avid Booth #403: CHI's 9th Annual BioProcessing Summit, Boston http://www.bioprocessingsummit.com
~Sep7: FY'18Q1 (qe 7-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Sep8-12: 42nd ESMO Eur. Cancer Congress”, Madrid http://www.esmo.org/Conferences/ESMO-2017-Congress
...Peregrine Exhibiting: Booth #257
Sep25-28/Avid Booth #918: Informa’s BPI’17: BioProcess Intl. Conf. & Exhibition, Boston https://lifesciences.knect365.com/bioprocessinternational
Oct2/NCI Scientist Gregoire Altan-Bonnet(MSKCC ties), AACR’s Tumor Immunotherapy Conf., Boston http://tinyurl.com/y74v76go
...“Long-Lived Disruption of Inflammation Stems from the Catch-and-Release of Cytokines Mediated by Surface Phosphatidylserine in Tumors”
~Oct12: Peregrine's Annual Shareholder’s Meeting (2016 attendee reports: http://tinyurl.com/jx7ouay )
Dec11-15/Avid Booth #311: KNect365’s Antibody Eng. & Therapeutics Conf., SanDiego https://lifesciences.knect365.com/antibody-engineering-therapeutics
~Dec11: FY'18Q2 (qe 10-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Jan20-22 2018: Phacilitate’s Immunotherapy World Forum, Miami http://www.immunotherapyforum.com
...Jan18 12:30-12:45, Joe Shan(VP/Reg+Clin): “Turning up the Heat: PS-Targeting Antibodies Modulate the Tumor Microenvironment & Enhance Checkpoint Blockade”
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
7-20-17: Large Ownership Summary(34%), RONIN Letters/PPHM Comments
Large Ownership now ~15.3mm shares, 34.0% of 45mm O/S. (Ronin+SW/Stafford+White, Eastern Cap./K.Dart, Institutions)
#1: 10-30-15: Kenneth Dart (Eastern Capital) acquires 9.6% stake (4,300,992sh.) in PPHM http://tinyurl.com/y95yskck
...3,777,183 COMMON – 8.4% of 45,069,188 common O/S at 7-10-17 (total beneficial=4,300,992 if Pref. conv. x1.19 to Common, 9.6%)
...440,000 PREFERRED – 26.7% of 1,647,760 preferred O/S at 1-31-17
#2: 7-14-17/13D: Group Ronin Trading/SWInvest (John Stafford III+Stephen White) acquires 8.8% stake (3,952,446sh.) in PPHM http://tinyurl.com/y7ezqvm9
...3,801,139 COMMON – 8.4% of 45,069,188 common O/S at 7-10-17 (total beneficial=3,952,446 if Pref. conv. x1.19 to Common, 8.8%)
...127,099 PREFERRED – 7.7% of 1,647,760 preferred O/S at 1-31-17
NOTE: ALL historical common #’s adjusted for the 1:7 R/S eff. 7-10-17.
RONIN/SW 13D SUMMARY:
13D TransDates COMMON-CHG PREF-CHG ENDING-COMMON ENDING-PREF.
3-2-17 1/20/17-3/1/17 +2,947,425 +51,364 2,947,425 51,364 http://tinyurl.com/jr42u23
3-10-17 3/2/17-3/9/17 +433,509 +25,661 3,380,934 77,025 http://tinyurl.com/ydxra96u
4-17-17 3/28/17-4/10/17 0 +23,334 3,380,934 100,359 http://tinyurl.com/lanjddc
5-19-17 5/1/17-5/17/17 0 +23,140 3,380,934 123,499 http://tinyurl.com/mgnn92x
6-20-17 3/10/17-6/16/17 +378,170 0 3,759,105 123,499 http://tinyurl.com/y76q5rqu
6-29-17 6/21/17 +7,143 0 3,766,248 123,499 http://tinyurl.com/y9sp8bfv
7-14-17 6/29/17-7/7/17 +34,891 +3,600 3,801,139 127,099 http://tinyurl.com/ybra4s69
SPLITOUT 13D GROUP into Ronin(John Stafford III) and SW-Partners(Stephen White):
Ronin Trading (Stafford) 3,173,391 115,299
SW-Partners (White) 627,748 11,800
See 13D Details Below.
- - - - - - - - - - - - - - -
Plus, INSTITUTIONS a/o 3-31-17 (+ 7-20-17 Tappan/13G): 7,075,268sh. = 15.7% (of $45mm) http://www.nasdaq.com/symbol/pphm/institutional-holdings
TOP5:
Kennedy Capital Mgt. 1,247,224 +164,952
Tappan Street Partners 914,304 +914,304
...Includes: **7-20-17 13G: Tappan adds +1,384,380, now 2,298,684=5.1% http://tinyurl.com/y94egwwk
Vanguard Group 882,964 +267,438
Blackrock (Larry Fink, CEO) 855,455 +177,856
Renaissance Technologies 439,673 +6,259
Hutschi, that Dana-Farber patent App is a continuation of previously granted patent #9,492,518 that was originally filed 10-4-2007 and, from what I can tell, most recently approved (probably thru 1 or more subsequent iterations) on 11-15-2016...
U.S. Patent #9,492,518
”Tumor Immunity - Disclosed herein are materials and methods for treating cancer. In particular, compositions for stimulating tumor immunity through modulation of MFG-E8 are provided.”
Inventors: Dranoff, Glenn (Lexington, MA), Jinushi, Masahisa (Tokyo)
Assignee: Dana-Farber Cancer Institute (Boston)
Filed: 10-4-2007, PCT Pub. Date: 4-10-2008, Approved: 11-15-2016
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9,492,518.PN.&OS=PN/9,492,518&RS=PN/9,492,518
= = = = =CONTINUATION:
U.S. Patent Appl. #20170224793: Filed: 9/26/2016, Pub: 8/10/2017
http://www.freepatentsonline.com/y2017/0224793.html
“This application is a continuation of U.S. patent application #12/444,047, filed Mar. 4, 2010 and issued as U.S. Pat. #9,492,518 on Nov. 15, 2016, which is the U.S. National Phase of Intl. Patent Appl. #PCT/US07/80446, filed Oct. 4, 2007, which claims priority to U.S. Provisional Patent Appl.# 60/828,177, filed Oct. 4, 2006. The contents of each application listed above are incorporated herein by reference in their entireties.”
SUMMARY:
Methods and compositions for cancer therapy are provided. In particular, the methods and compositions described herein stimulate immune-mediated tumor destruction. The present invention is based, in part, on the discovery that conditions that result in the downregulation of MFG-E8 can potentiate GM-CSF stimulated tumor destruction to provoke a clinical anti-tumor response.
. . .
In another embodiment, the MFG-E8 inhibitor is selected from the group consisting of an anti-MFG-E8 antibody, an anti-phosphatidylserine antibody, an MFG-E8 polypeptide that lacks the ability to bind integrins; and an MFG-E8 polypeptide that lacks the ability to bind phosphatidylserine. The antibody can be a monoclonal antibody, a polyclonal antibody, an Fab fragment, a chimeric antibody, a humanized antibody or a single chain antibody. Regardless of the precise molecular form of the antibody, the antibody is a pharmaceutically pure antibody.
ANTIBODIES:
An MFG-E8 inhibitor can be an antibody. In one embodiment, the antibody can be an anti-MFG-E8 antibody. In another embodiment, the antibody can be an anti-PS antibody. Anti-PS antibodies and ligands for binding PS are described in U.S. Pat. Nos. 6,406,693, 6,818,213, 6,312,694, and 6,783,760 and in Beck et al. 2006 Int J Cancer 118:2639-43. Anti-PS antibodies e.g., Bavituximab (Peregrine Pharmaceuticals), are also described on the NCI trials database at http//canger.gov/clinical trials. In another embodiment, the antibody can be an antibody that specifically recognizes and blocks the activity of a molecule that functions in the uptake of PS. Examples of PS-uptake targets include Del-1 (see for example, without limitation, NP_005702, GI:31317224), Gas6 (see for example, without limitation, NP_000811, GI:4557617), Mer (see for example, without limitation, NP_006334, GI:66932918) and members of the Tyro family (see for example, without limitation, NP_006284, GI:27597078.) As used herein, useful antibodies can include: monoclonal and polyclonal antibodies, single chain antibodies, chimeric antibodies, bifunctional/bispecific antibodies, humanized antibodies, human antibodies, and complementary determining region (CDR)-grafted antibodies, that are specific for the target protein or fragments thereof, and also include antibody fragments, including Fab, Fab', F(ab')2, scFv, Fv, camelbodies, or microantibodies.
MFG-E8: https://en.wikipedia.org/wiki/MFGE8
“Of the 7 patients who have proceeded to surgery, 1 patient's tumor demonstrated a pathologic complete response… Trial enrollment continues at the 3 mg/kg dose level. Toxicities have been relatively mild to date...”
5th IST Trial (Bavi+Capecitabine+RAD) vs. Rectal Cancer (Ph1, open-label, 1arm, n=18)
...7-31-17/Jrnl-Clin-Oncol(UTSW): Phase I update http://www.redjournal.org/article/S0360-3016(15)01602-8/fulltext
The Human Body – the complexity is mind-boggling. And this is just the tip of the iceberg of the whole Molecular Biology/Immunology World. Equally amazing to me is how talented humans like these ever figured all this out. And do they know everything? – certainly not even close. All I can do is, to coin a millennials phrase, SMH.
8-2-17/Front.Immunol: “Anti-inflammatory Mechanisms Triggered by Apoptotic Cells during Their Clearance”
Dept of Biochemistry & Molecular Biology, Univ. of Debrecen, Hungary
http://journal.frontiersin.org/article/10.3389/fimmu.2017.00909/full
Apoptotic cell death is a determinant contributing factor to the cell turnover in most of the tissues. The silent removal of apoptotic cells maintains tissue integrity under healthy conditions and its anti-inflammatory nature contributes to the resolution of inflammation (Fig. 1).
FIG. 1
Mechanisms of the anti-inflammatory effects of apoptotic cells. Apoptotic cells release various anti-inflammatory molecules, such as transforming growth factor (TGF)-B, interleukin (IL)-10, annexin I, thrombospondin-1 (TSP-1), fractalkine to inhibit pro-inflammatory cytokine formation of phagocytes. Once released from the apoptotic cells via a caspase-regulated pannexin channel, ATP is fast degraded to adenosine by the cell surface 5' nucleotidase of engulfing macrophages. Adenosine then triggers macrophage adenosine A2A receptors to suppress the NO-dependent formation of neutrophil migration factors, or in an inflammatory milieu the lipopolysaccharide (LPS)-induced pro-inflammatory cytokine formation by phagocytes. Apoptotic cells express phosphatidylserine (PS), which activates various PS sensing phagocytic receptors. Many of these receptors initiate such intracellular signaling pathways that interfere with the pro-inflammatory cytokine formation of phagocytes. Following engulfment, the lipid content of the apoptotic cells activate the nuclear lipid sensing receptors [liver X receptors (LXRs) and perixosome proliferator-activated receptors (PPARs)], which in ligated form can also interfere with the NF-kB-driven pro-inflammatory cytokine formation. And, finally, engulfing macrophages release TGF-B, IL-10, and retinoids, which act in a paracrine or autocrine fashion to amplify and sustain the anti-inflammatory response and strongly contribute to the formation of the regulatory T cells to prevent the development of autoimmunity./fimmu.2017.00909/full
Huts, Dr.Birge’s(Rutgers) 9-2016 PS Article reported here:
Sept25-28 2016: “2nd CRI-AACR-CIMT-EATI Intl. Cancer Immunotherapy Conf.”, NYC
#B119 “Characterization of a Phosphatidylserine, TAM Receptor (Tyro3, Axl, Mertk), PDL1 Axis in Breast Cancer”
Canan Kasikara 1, Sushil Kumar 1, Ke Geng 1, Viral Davre 1, Cyril Empig 2, Bruce Freimark 2, Michael Gray 2, Kyle Schlunegger 2, Jeff Hutchins 2, Sergei V. Kotenko 1, Raymond B. Birge 1
1=Rutgers, New Jersey Medical School, Newark
2=Peregrine Pharmaceuticals, Tustin
SEE: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129934274
ES18, ALL existing ATM’s are fully-executed a/o 7-14-17/10K. There can be no further ATM sales until PPHM enters another agreement with a firm like Noble or MLV and files a Form 424B5, like they’ve always done in the past.
See: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=133107514
Known Upcoming Events, Large-Shareholders(34%), RONIN-PPHM HISTORY: updated 7-31-17 with PPHM’s PR, “Peregrine Provides Strategic Update”...
KNOWN UPCOMING:
Jul27: Final Settlement Hearing for 2013 Shareholder Derivative CA Lawsuit vs. BOD http://tinyurl.com/y982h3rt
Aug15-16: CBI’s MES 2017 (Mfg. Execution Systems), Orlando http://tinyurl.com/ya4twmbj
...Aug16/8:45am: Mehron Mirian (SeniorMgr./QA Validation), "MES AUDIT DEEP DIVE Computerized System Audit"
Aug21-25/Avid Booth #403: CHI's 9th Annual BioProcessing Summit, Boston http://www.bioprocessingsummit.com
~Sep7: FY'18Q1 (qe 7-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Sep25-28/Avid Booth #918: Informa’s BPI’17: BioProcess Intl. Conf. & Exhibition, Boston https://lifesciences.knect365.com/bioprocessinternational
Oct2/NCI Scientist Gregoire Altan-Bonnet(MSKCC ties), AACR’s Tumor Immunotherapy Conf., Boston http://tinyurl.com/y74v76go
...“Long-Lived Disruption of Inflammation Stems from the Catch-and-Release of Cytokines Mediated by Surface Phosphatidylserine in Tumors”
~Oct12: Peregrine's Annual Shareholder’s Meeting (2016 attendee reports: http://tinyurl.com/jx7ouay )
Dec11-15/Avid Booth #311: KNect365’s Antibody Eng. & Therapeutics Conf., SanDiego https://lifesciences.knect365.com/antibody-engineering-therapeutics
~Dec11: FY'18Q2 (qe 10-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
7-20-17: Large Ownership Summary(34%), RONIN Letters/PPHM Comments
Large Ownership now ~15.3mm shares, 34.0% of 45mm O/S. (Ronin+SW/Stafford+White, Eastern Cap./K.Dart, Institutions)
#1: 10-30-15: Kenneth Dart (Eastern Capital) acquires 9.6% stake (4,300,992sh.) in PPHM http://tinyurl.com/y95yskck
...3,777,183 COMMON – 8.4% of 45,069,188 common O/S at 7-10-17 (total beneficial=4,300,992 if Pref. conv. x1.19 to Common, 9.6%)
...440,000 PREFERRED – 26.7% of 1,647,760 preferred O/S at 1-31-17
#2: 7-14-17/13D: Group Ronin Trading/SWInvest (John Stafford III+Stephen White) acquires 8.8% stake (3,952,446sh.) in PPHM http://tinyurl.com/y7ezqvm9
...3,801,139 COMMON – 8.4% of 45,069,188 common O/S at 7-10-17 (total beneficial=3,952,446 if Pref. conv. x1.19 to Common, 8.8%)
...127,099 PREFERRED – 7.7% of 1,647,760 preferred O/S at 1-31-17
NOTE: ALL historical common #’s adjusted for the 1:7 R/S eff. 7-10-17.
RONIN/SW 13D SUMMARY:
13D TransDates COMMON-CHG PREF-CHG ENDING-COMMON ENDING-PREF.
3-2-17 1/20/17-3/1/17 +2,947,425 +51,364 2,947,425 51,364 http://tinyurl.com/jr42u23
3-10-17 3/2/17-3/9/17 +433,509 +25,661 3,380,934 77,025 http://tinyurl.com/ydxra96u
4-17-17 3/28/17-4/10/17 0 +23,334 3,380,934 100,359 http://tinyurl.com/lanjddc
5-19-17 5/1/17-5/17/17 0 +23,140 3,380,934 123,499 http://tinyurl.com/mgnn92x
6-20-17 3/10/17-6/16/17 +378,170 0 3,759,105 123,499 http://tinyurl.com/y76q5rqu
6-29-17 6/21/17 +7,143 0 3,766,248 123,499 http://tinyurl.com/y9sp8bfv
7-14-17 6/29/17-7/7/17 +34,891 +3,600 3,801,139 127,099 http://tinyurl.com/ybra4s69
SPLITOUT 13D GROUP into Ronin(John Stafford III) and SW-Partners(Stephen White):
Ronin Trading (Stafford) 3,173,391 115,299
SW-Partners (White) 627,748 11,800
See 13D Details Below.
- - - - - - - - - - - - - - -
Plus, INSTITUTIONS a/o 3-31-17 (+ 7-20-17 Tappan/13G): 7,075,268sh. = 15.7% (of $45mm) http://www.nasdaq.com/symbol/pphm/institutional-holdings
TOP5:
Kennedy Capital Mgt. 1,247,224 +164,952
Tappan Street Partners 914,304 +914,304
...Includes: **7-20-17 13G: Tappan adds +1,384,380, now 2,298,684=5.1% http://tinyurl.com/y94egwwk
Vanguard Group 882,964 +267,438
Blackrock (Larry Fink, CEO) 855,455 +177,856
Renaissance Technologies 439,673 +6,259
Next post updated w/PPHM’s PR, “Peregrine Provides Strategic-Update”
N40K, here's the Nov’15 SITC Conf. you attended (Natl.Harbor MD)
11-9-15 SITC'15: New Bavi+Checkpoint Inhibitors preclin. data (DUKE's Herbert K. Lyerly + PPHM + UTSW)
...Also, collab. with Dr. Bernard Fox (Immunotherapist/Earle A. Chiles Res.Inst.) on new Immuno-Profiling Clinical Test (Opal 6-plex quantitative IF Assay), PPHM roundtable with Raymond Birge (Rutgers), Douglas Graham (Emory), Dmitry Gabrilovich (Wistar), Rolf Brekken (UTSW), Maria Karasarides (AstraZeneca)
”Combining Bavi w/anti-PD-1 significantly enhanced O/S…
significantly increases CD45+, CD8+ and CD3+ T-cells…
led a prolonged anti-tumor immune response which
protected the animals against a re-challenge w/same tumor.”
SEE:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=118351795
Here’s very positive statement by MSKCC’s T.Merghoub, PhD, Co-Dir. of the Ludwig Collaborative Lab at Memorial Sloan Kettering Cancer Center (member of Jedd Wolchok’s Lab)...
Dr. Taha Merghoub (MSKCC) 4-3-17: http://tinyurl.com/lxlltd6
“While adoptive T cell transfer remains one of the most exciting new approaches to treating cancer, to date the toxicity associated with the treatment has limited its potential. We are encouraged that these study results [AACR’17 PPHM/MSKCC #1651] showed that the combination of anti-PS and adoptive T cell treatment [ACT / CAR T] led to enhanced anti-tumor effect without any evidence of additional off-target side effects. “We believe that these findings may support potential applications for this combination in solid tumors in the future.”
That statement came from PPHM’s 4-3-17 AACR’17 PR, re: the joint MSKCC/PPHM poster #1651, “Targeting with Adoptive T Cell Transfer [ACT/CAR T] Eliminates Advanced Tumors without Off-Target Toxicities in a Melanoma Preclinical Model”
More on AACR'17 #1651:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=133245961
Wolchok Lab, Dr. Taha Merghoub: https://www.mskcc.org/research-areas/labs/members/taha-merghoub-01
= = = = = = = = = = = = = = = =
“Immunotherapy drugs release this brake and empower immune cells to fight the cancer.
Sometimes the immune system needs a tune-up before it can fight cancer.
Immune cells can be removed from the body, armed with new proteins that can target
cancer cells, and given back to a patient in large numbers.
Once inside the body, the modified immune cells recognize and attack the cancer.
This approach is called CAR T Cell therapy. [an Adoptive Cell Transfer “ACT” strategy]
Despite the promise of immunotherapy, not everybody responds.
MSKCC scientists are exploring ways to improve immunotherapy.”
https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
PPHM’s Bruce Freimark (Res.Dir/PreClin) speaking today at Lung-Cancer-Conf/Boston
Jul25-26 2017: “Neo-Synth’s Precision: Lung Cancer - World R&D Summit”, Boston
“Precision: Lung Cancer (A Global Pharma R&D Summit) will bring together scientists & business leaders from pharma, biotech & academia, using extensive networking sessions to forge meaningful collaborations.”
http://precisionlungcancer.com ( http://neo-synth.com/#aboutus )
7-25-17 12:00pm (Day1): “Overriding Phosphatidylserine-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”
Bruce Freimark (Research Dir., Preclinical Oncology), Peregrine Pharmaceuticals
KNOWN UPCOMING EVENTS:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=133208701
= = = = = = = = = = = =
BAVI MOA 5-11-16 Breast Cancer Res. article, B.Freimark/M.Gray/CW.Hughes-et-al, “PS-Targeting/Bavi Combo w/Anti-PD1/PDL1 in Triple.Neg-MBC” http://tinyurl.com/zxu882y
...”our observations demonstrate that including PS-targeting antibodies such as bavituximab can enhance the anti-tumor activity of anti-PD-1/PD-L1 treatments, not only by increasing TIL responses but also by inhibiting cytokines stimulated by single-agent anti-PD-1 therapy that serve to suppress the immune response & promote tumor progression.”
N40k, here’s the MSKCC/Wolchok AACR’17 #1651 you spoke of. Two things kill me about it: the TITLE they chose for it (“CAR-T + AntiPS...Eliminates Advanced Tumors...” - you don’t see that phrase much out of top scientists), and the fact Jedd Wolchok was author/co-author of 9 AACR’17 abstracts: 5 were re: human trials, one was MSKCC-only, one w/Genocea re: screening, and the ONLY 2 others, involving pre-clin. I-O testing by the MSKCC lab, were with PEREGRINE & AntiPS – that blew my mind then, and it still does.
...MORE on the PPHM+MemSloan collab here:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=130490016
= = = = = = = = = = = = = = = =
AACR’17 2. 4-3-17/8am #1651 - Session: TUMOR MICROENVIRONMENT & CHECKPOINTS [Joint PPHM & Memorial Sloan Kettering]
“Targeting Phosphatidylserine in Combination with Adoptive T Cell Transfer Eliminates Advanced Tumors without Off-Target Toxicities in a Melanoma Preclinical Model” <=NEW(2nd) MSK STUDY
=> Daniel Hirschhorn-Cymerman 1, Sara Sara Schad 1, Sadna Budhu 1, Zhong Hong 1, Xia Yang 1, Hutchins T. Jeff 2, Bruce D. Freimark 2, Michael J. Gray 2, Jedd Wolchok 1, Taha Merghoub [Memorial Sloan Kettering]
1=Memorial Sloan Kettering CC, NYC [ http://www.mskcc.org/research-areas/labs/jedd-wolchok ]
2=Peregrine Pharmaceuticals
---------------------
FROM PPHM’s 4-3-17 PR: http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=1019762
…”Latest Findings from Ongoing Collaboration with Memorial Sloan Kettering (MSK) Support Potential Applications for Combining CAR T & Anti-PS in Treatment of Solid Tumors”… For this study, a team of MSK researchers led by cancer immunotherapy thought-leaders, Taha Merghoub, Ph.D. and Jedd D. Wolchok, M.D., Ph.D., evaluated and compared the anti-tumor activity and off-target toxicities of adoptive T cell transfer therapy in combination with either PS-targeting antibodies or anti-OX40 antibodies in mice with advanced melanomas. Whereas PS-targeting and anti-OX40 demonstrated comparable tumor regression when administered in combination with transferred adoptive T cells, only the PS-targeting combination achieved these results without any off-target toxicities. By contrast, the anti-OX40 treatment combination triggered off-target inflammatory destruction of healthy tissues. Additional study results demonstrated that the PS-targeting antibodies decreased tumor-induced immunosuppression as evidenced by a decrease in immunosuppressive regulatory T cells (Tregs) and M2 macrophages. This finding is consistent with Peregrine’s belief that bavituximab may modulate the immunosuppressive tumor microenvironment and enhance the activity of immunotherapy agents.
Taha Merghoub, Ph.D., Co-Dir. of the Ludwig Collaborative Laboratory at MSK:
“While adoptive T cell transfer remains one of the most exciting new approaches to treating cancer, to date the toxicity associated with the treatment has limited its potential. We are encouraged that these study results showed that the combination of anti-PS and adoptive T cell treatment led to enhanced anti-tumor effect without any evidence of additional off-target side effects. “We believe that these findings may support potential applications for this combination in solid tumors in the future.”
Joseph Shan, Peregrine’s VP of Clinical & Regulatory Affairs:
“These study results provide further support for our belief that anti-PS agents such as bavituximab can play an important role as part of combination cancer treatments. This is directly tied to the agents’ ability to modulate the tumor microenvironment to combat the immunosuppression that limits the activity of CAR T and immunotherapies. Importantly, we are now also seeing evidence that this targeted modulation of the tumor microenvironment by anti-PS allows for enhanced activity of these other treatments without triggering any off-target toxicities. This is opposed to other conventional immunotherapies such as anti-OX40 with systemic mechanisms of action. We believe this advantageous tolerability profile will be a key benefit in positioning anti-PS agents for inclusion in optimal combination cancer regimens.”
-----------
ABSTRACT #1651:
A viable strategy to treat advanced cancers includes transferring of tumor-specific T cells. T cells that recognize tumor antigens can be expanded and reinvigorated ex-vivo. Furthermore, autologous T cells can be genetically modified to express anti-tumor T cell receptors [TCRs] or chimeric antigen receptors [CARs]. Although the potency and specificity of tumor-specific T cells can be manipulated ex-vivo, once re-infused into patients, the T cells are subjected to immunosuppressive mechanisms established by the tumor. An important immune checkpoint regulator within tumors is phosphatidylserine (PS). Innate immune cells exposed to PS secrete suppressive cytokines and chemokines that can significantly impair the function and activation of anti-tumor T cells. Therefore, monoclonal antibodies that block PS activity can increase the anti-tumor potency of transferred T cells to treat aggressive cancers. Here we show that a PS targeting monoclonal antibody in combination with CD4+ T cells that recognize the melanoma antigen Trp1 can regress very advanced melanomas in all treated mice. Combination of anti-Trp1 CD4+ T cells with other immunomodulatory modalities such as anti-OX40 antibodies, can achieve equivalent treatment rates but these are typically accompanied by severe immune related adverse events. In contrast, in this setting, PS blockade did not show any off-target toxicities. Flow cytometry analysis revealed lower levels of CD206 expression concomitant with higher activation markers in macrophages and neutrophils in tumors from anti-PS treated mice. These results suggest that diminishing suppressive mechanisms locally in adoptive transfer protocols is a highly desirable strategy that can eliminate tumors while minimizing related adverse events.
POSTER #1651 IMAGE: http://www.peregrineinc.com/images/stories/pdfs/aacr2017hirschhorn.pdf
---------------------
8-2015: Presently there are 3 types of Adoptive Cell Transfer (ACT) using effector T cells that are advancing on a path towards regulatory approval:
1. TILs (tumor infiltrating lymphocytes) have been developed with slow but continuing progress over several decades.
2. CARs (chimeric antibody receptors) – newer gene-modified T cells strategy
3. TCRs (T-cell receptors) – newer gene-modified T cells strategy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4507286/
...“Adoptive T cell transfer is like ‘giving patients a living drug’,” states Renier J. Brentjens, MD/PhD, of Memorial Sloan Kettering Cancer Center (MSKCC).
… https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
...“Adoptive T cell therapy (ACT) is one stone in this new pillar, a potentially powerful approach to cancer treatment that relies on the infusion of tumor-specific T cells.”
… https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4327320
MSK Tweet 4-3-17 https://twitter.com/sloan_kettering :
...See bottom right: “SWIM” - Swim Across America http://www.swimacrossamerica.org
= = = = = = = = =
Interesting 3-31-17 Sloan Kettering Tweet re: AACR’17
3-31-17 9:20amET “Getting ready for #AACR17? #Immunotherapy will be a hot topic. Learn more about how it works (video). @AACR”
https://twitter.com/sloan_kettering
Points to this 4-2016 Video (1:20):
“Immunotherapy – How It Works” https://www.youtube.com/watch?v=COQ1AeoGyco
Beg@:39:
“Immunotherapy drugs release this brake and empower immune cells to fight the cancer.
Sometimes the immune system needs a tune-up before it can fight cancer.
Immune cells can be removed from the body, armed with new proteins that can target cancer cells, and given back to a patient in large numbers.
Once inside the body, the modified immune cells recognize and attack the cancer.
This approach is called CAR T cell therapy. [an Adoptive Cell Transfer “ACT” strategy]
Despite the promise of immunotherapy, not everybody responds.
MSKCC scientists are exploring ways to improve immunotherapy.”
=============AND, THIS 3-23-17 PARKER FOUNDATION RELEASE ON AACR’17:
3-23-17: “Parker Institute for Cancer Immunotherapy Scientists to Present Research on Checkpoint Inhibitors, Adoptive Cell Therapy, and Other Advances in Immuno-oncology at AACR 2017”
Investigators affiliated with the Parker Institute for Cancer Immunotherapy will present some of the most anticipated immuno-oncology research at the 2017 AACR Annual Meeting. The event takes place at the Walter E. Washington Convention Center in Washington, DC, April 1-5 2017. . .
Other adoptive cell therapy abstracts of interest:
• ”Targeting Phosphatidylserine in Combination with Adoptive T Cell Transfer Eliminates Advanced Tumors without Off-Target Toxicities in a Melanoma Preclinical Model” [see http://tinyurl.com/nx5q5os ]
The principal investigator is Taha Merghoub, PhD, Parker Institute member researcher at Memorial Sloan Kettering Cancer Center. Co-authors include Parker Institute Center Director Jedd Wolchok, MD, PhD, at Memorial Sloan Kettering Cancer Center.
http://www.parkerici.org/media/2017/parker-institute-for-cancer-immunotherapy-scientists-to-present-research-on
----------ACT NOTES:
NOTE1:
From 3-2014 Immunotherapy article: “Cancer immunotherapy, particularly adoptive cell transfer (ACT), has shown great promise in the treatment of patients with late-stage disease, including those who are refractory to std. Therapies” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372895
NOTE2:
The Parker Foundation: “The Immunotherapy Dream Team”
Through the support from SEAN PARKER, Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) formed an Immunology Research Dream Team dedicated to cancer immunology: “Immunologic Checkpoint Blockade & Adoptive Cell Transfer in Cancer Therapy.” The Immunotherapy Dream Team is focused on 2 approaches for this translational cancer research project, which will unite laboratory & clinical efforts towards the immunological treatment, control, and prevention of cancer.
The 1st is investigating blockades (by inhibitory molecules called “checkpoints”) of T lymphocytes’ inhibitory receptors, which block immune responses; and the use of antibodies to remove the checkpoints, once again allowing white blood cells called T lymphocytes to kill the cancer cells.
Second, the Immunotherapy Dream Team is pursuing multiple Adoptive Cell Transfer (ACT) approaches, which increase immunity.”
DREAM TEAM LEADERSHIP: 10 scientists, incl. MSKCC’s Jedd D. Wolchok & Michel Sadelain.
http://parker.org/initiatives/immunotherapy
-------
NOTE: Mem. Sloan’s Dr. Jedd. Wolchok was co-author of 9 AACR’17 abstracts. 2 of the 9 are w/PPHM re: PS-Targeting. With biotechs, he had one each with Genocea Biosciences(ex-vivo screening), Infinity Pharm(Ph1), Leap Ther.(Ph1), and two with BMS(Ph1+3). The 8th was MSKCC ONLY, and the 9th was jointly w/Cedars-Sinai/LA. http://www.abstractsonline.com/pp8/#!/4292 .
PEREGRINE (Joint Mem.Sloan Kettering Wolchok Lab & PPHM):
1. 4-2-17 #574 “Phosphatidylserine Targeting Antibody in Combination with Tumor Radiation & Immune Checkpoint Blockade Promotes Anti-Tumor Activity in Mouse B16 Melanoma” <=Same as SITC’16 11-14-16.
2. 4-3-17 #1651 “Targeting Phosphatidylserine in Combination With Adoptive T Cell Transfer Eliminates Advanced Tumors Without Off-Target Toxicities in a Melanoma Preclin. Model” <=NEW/2nd PPHM+MSK.
NON-PEREGRINE:
3. (MSK ONLY): 4-2-17 #874 “Lifting the iron curtain: Imaging cellular barriers to combination chelation-immune checkpoint therapy”
4. (MSK & Genocea Bio. http://www.genocea.com GNCA/$130mm MktCap) 4-2-17 #632 “Genome-scale neoantigen screening using ATLAS prioritizes candidate antigens for immunotherapy in a NSCLC patient”
5. (MSK & Cedars-Sinai/LA) 4-4-17 #4705 “CTLA4 blockade with HER2-directed therapy yields clinical benefit in women undergoing radiation therapy for HER2+ breast cancer brain metastases (n=20 human pilot study)”
6. (MSK & Infinity Pharm.) 4-4-17 #CT089 “A Ph1, first-in-human study of IPI-549, a PI3K-y inhibitor, as monotherapy & in combo w/nivolumab in adv. solid tumors”
7. (MSK & Leap Ther.) 4-2-17 #CT018 “Intratumor & peripheral Treg modulation as a pharmacodynamic biomarker of the GITR agonist antibody TRX-518 in the 1st in-human trial”
8. (MSK & BMS) 4-3-17 #CT073 “(Ph1) Immunomodulatory effects of NIVO+IPI or NIVO/mono in adv. melanoma: CheckMate038”
9. (MSK & BMS) 4-3-17 #CT075 “OS results from a Ph3 of NIVO+IPI in treatment-naïve pts w/adv. Melanoma: CheckMate067”
FYI: JULY 2014: Mem. Sloan’s Jedd Wolchok Video: “Immunotherapy for Metastatic Melanoma - PD-1 Clinical Trials”… Dr. Wolchok (1:42), “We will not rest until every patient can have a durable response.” http://cyberspaceandtime.com/kvWeW8Zt0sU.video (1:49)
DJ, this thread on the $67mm remaining on the S-3/Shelf the other day w/Corp...
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=133122423
Known Upcoming Events, Large-Shareholders(34%), RONIN-PPHM HISTORY: updated 7-21-17 with PPHM CEO Steve King’s response letter to PPHM’s employees re: Ronin/John Stafford’s 7-20-17 “Letter to Employees of Peregrine”. Also note Tappan St. Partner’s 7-20-17 13G (Tappan adds +1,384,380sh. => now 2,298,684=5.1% Stake)...
KNOWN UPCOMING:
Jul25: Neo-Synth’s "Precision: Lung Cancer - World R&D Summit", Boston http://tinyurl.com/ydcxlkja
...12:00pm: Bruce Freimark (Res.Dir/PreClin-Oncol), “Overriding PS-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”
Jul27: Final Settlement Hearing for 2013 Shareholder Derivative CA Lawsuit vs. BOD http://tinyurl.com/y982h3rt
Aug15-16: CBI’s MES 2017 (Mfg. Execution Systems), Orlando http://tinyurl.com/ya4twmbj
...Aug16/8:45am: Mehron Mirian (SeniorMgr./QA Validation), "MES AUDIT DEEP DIVE Computerized System Audit"
Aug21-25/Avid Booth #403: CHI's 9th Annual BioProcessing Summit, Boston http://www.bioprocessingsummit.com
~Sep7: FY'18Q1 (qe 7-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Sep25-28/Avid Booth #918: Informa’s BPI’17: BioProcess Intl. Conf. & Exhibition, Boston https://lifesciences.knect365.com/bioprocessinternational
Oct2/NCI Scientist Gregoire Altan-Bonnet(MSKCC ties), AACR’s Tumor Immunotherapy Conf., Boston http://tinyurl.com/y74v76go
...“Long-Lived Disruption of Inflammation Stems from the Catch-and-Release of Cytokines Mediated by Surface Phosphatidylserine in Tumors”
~Oct12: Peregrine's Annual Shareholder’s Meeting (2016 attendee reports: http://tinyurl.com/jx7ouay )
Dec11-15/Avid Booth #311: KNect365’s Antibody Eng. & Therapeutics Conf., SanDiego https://lifesciences.knect365.com/antibody-engineering-therapeutics
~Dec11: FY'18Q2 (qe 10-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
7-24-17: Large Ownership Summary(34%), RONIN Letters/PPHM Comments
Large Ownership now ~15.3mm shares, 34.0% of 45mm O/S. (Ronin+SW/Stafford+White, Eastern Cap./K.Dart, Institutions)
#1: 10-30-15: Kenneth Dart (Eastern Capital) acquires 9.6% stake (4,300,992sh.) in PPHM http://tinyurl.com/y95yskck
...3,777,183 COMMON – 8.4% of 45,069,188 common O/S at 7-10-17 (total beneficial=4,300,992 if Pref. conv. x1.19 to Common, 9.6%)
...440,000 PREFERRED – 26.7% of 1,647,760 preferred O/S at 1-31-17
#2: 7-14-17/13D: Group Ronin Trading/SWInvest (John Stafford III+Stephen White) acquires 8.8% stake (3,952,446sh.) in PPHM http://tinyurl.com/y7ezqvm9
...3,801,139 COMMON – 8.4% of 45,069,188 common O/S at 7-10-17 (total beneficial=3,952,446 if Pref. conv. x1.19 to Common, 8.8%)
...127,099 PREFERRED – 7.7% of 1,647,760 preferred O/S at 1-31-17
NOTE: ALL historical common #’s adjusted for the 1:7 R/S eff. 7-10-17.
RONIN/SW 13D SUMMARY:
13D TransDates COMMON-CHG PREF-CHG ENDING-COMMON ENDING-PREF.
3-2-17 1/20/17-3/1/17 +2,947,425 +51,364 2,947,425 51,364 http://tinyurl.com/jr42u23
3-10-17 3/2/17-3/9/17 +433,509 +25,661 3,380,934 77,025 http://tinyurl.com/ydxra96u
4-17-17 3/28/17-4/10/17 0 +23,334 3,380,934 100,359 http://tinyurl.com/lanjddc
5-19-17 5/1/17-5/17/17 0 +23,140 3,380,934 123,499 http://tinyurl.com/mgnn92x
6-20-17 3/10/17-6/16/17 +378,170 0 3,759,105 123,499 http://tinyurl.com/y76q5rqu
6-29-17 6/21/17 +7,143 0 3,766,248 123,499 http://tinyurl.com/y9sp8bfv
7-14-17 6/29/17-7/7/17 +34,891 +3,600 3,801,139 127,099 http://tinyurl.com/ybra4s69
SPLITOUT 13D GROUP into Ronin(John Stafford III) and SW-Partners(Stephen White):
Ronin Trading (Stafford) 3,173,391 115,299
SW-Partners (White) 627,748 11,800
See 13D Details Below.
- - - - - - - - - - - - - - -
Plus, INSTITUTIONS a/o 3-31-17 (+ 7-20-17 Tappan/13G): 7,075,268sh. = 15.7% (of $45mm) http://www.nasdaq.com/symbol/pphm/institutional-holdings
TOP5:
Kennedy Capital Mgt. 1,247,224 +164,952
Tappan Street Partners 914,304 +914,304
...Includes: **7-20-17 13G: Tappan adds +1,384,380, now 2,298,684=5.1% http://tinyurl.com/y94egwwk
Vanguard Group 882,964 +267,438
Blackrock (Larry Fink, CEO) 855,455 +177,856
Renaissance Technologies 439,673 +6,259
Next post updated 7-21-17 w/PPHM CEO/Steve-King’s response letter to PPHM’s employees re: Ronin/John Stafford’s 7-20-17 “Letter to Employees of Peregrine”.
All existing ATM’s are fully executed a/o 7-14-17/10K. There can be no further ATM sales until PPHM enters another agreement with a firm like Noble or MLV and files a Form 424B5, like they’ve always done in the past.
See: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=133107514
PPHM’s 10K Notes re: Avid FY18 & Beyond (FY18 Guidance announced 7-14-17: $50-55mm - http://tinyurl.com/yb4wulvu ). Also, see below for HALO’s comments about projected 2017/2018 Roche’s (reduced) demand for bulk rHuPH20 in their 3-31-17 10-Q filed 5-9-17...
From 4-30-17 10K iss. 7-14-17 - http://tinyurl.com/ycxu4l5n
Pg.2: “With respect to our CDMO business, FY17 was a record year for revenues, topping $57mm, a 30% growth over FY16. While we are pleased at the continued yr-over-yr revenue growth, we have also recently seen unanticipated decreases in mfg. demand from our largest customer [Halozyme] and a recent regulatory filing delay from our 2nd largest customer which will have some impact on our ability to grow the revenues from our CDMO business in FY18 and could impact our ability to achieve overall profitability by q/e July 31, 2018. However, we believe this to be temporary delay in revenue growth during FY18 and have recently secured 4 new customers and are continuing to focus on securing addl. customer business in order to better diversify our customer base. Our goal is to maintain profitability for Avid over the short term while positioning the business for long-term growth and attracting the resources necessary to continue to advance our promising research and development efforts.”
Pg.3: “FY18 Key Objectives - Our CDMO Business
* Expand our mfg. capacity through the installation & validation of two 2,000L single-use bioreactors in our Myford Facility to support the anticipated needs of a current customer
* Continue to diversify our customer base by securing addl. customers to support our future revenue growth beyond FY18.”
Pg.31: “We have been developing and mfg. biologics since 1993 in our Franklin biomfg. facility (the “Franklin Facility”) located at our current headquarters in Tustin and formed Avid in 2002 to offer these services to 3rd-party customers using. In March 2016, we expanded our mfg. capacity through the launch of our Myford biomfg. facility (“Myford Facility”), which doubled our mfg. capacity. The 42,000sf facility, which is our 2nd biomfg. facility, can accommodate single-use bioreactors up to the 2,000-liter mfg. scale. The Myford Facility was designed to accommodate a fully disposable biomfg. process for products in late stage clinical dev. to commercial. To date, Myford Facility has been utilized to complete a number of process validation runs for our 3rd-party customers, which may lead to future commercial production, and has supported the process validation of our internal product, bavituximab. The Myford Facility is located adjacent to our Franklin Facility. As we look to expand our CDMO business, in Feb. 2017, we leased an addl. 42,000sf of vacant warehouse space within the same building as our existing Myford Facility. The proximity of this space will allow us to utilize existing mfg. infrastructure that we believe should enhance our mfg. efficiencies and reduce the overall cost and timeframe to construct a 3rd biomfg. facility. Although we previously anticipated that the new mfg. facility would be constructed and ready for mfg. activities by mid-calendar year 2018, due to unanticipated changes in and/or timing of customer demand (as discussed above), we have decided to defer construction of this 3rd facility until demand from existing or potential new customers is expected to exceed the current mfg. capacity at our Franklin Facility & Myford Facility. Additionally, commencement of construction is also subject to our ability to raise sufficient addl. capital to support this expansion effort. As a result, we presently do not expect to commence construction of this 3rd facility prior to April 30, 2018.”
Pg33: “Excluding any future potential new business, we expect Avid revs for FY18 to slightly decline vs. FY17. Part of this decline is due to lower anticipated commitments from Halozyme (our largest customer) based on their most recent committed forecast (covering the 3 qtrs ending March 2018), which amount is expected to be partially offset by $10mm revenue that was expected to be recognized in FY17, but has been shifted to FY18 due to a delay in shipping product that was complete and ready for shipment as of fye 4-30-17.”
- - - - - - - - - - - -
HALO’s 3-31-17 10-Q filed 5-9-17: http://tinyurl.com/k6zb9uy (Halozyme)
Pg.41: "Product sales, net decreased in the 3mos ended 3-31-17 compared to the same period in 2016, due to a decrease in the sales of bulk rHuPH20 to Roche and a decrease in the sales of Hylenex. We expect that product sales of bulk rHuPH20 will fluctuate in future periods based on the needs of our collaborators. In 2016, we performed services for Roche to bring on-line a 2nd contract mfg. facility [Avid’s Myford] for bulk rHuPH20. Once this new [“Myford”] facility is approved, it will become the primary source for Roche of bulk rHuPH20. As a result, we anticipate Roche will deplete their existing inventory of rHuPH20 ahead of the transition to the new facility, which will result in lower bulk product sales during 2017 & 2018. We expect that future product sales of Hylenex to be flat or experience modest growth, although there may be periods with declining revenue as we experience competition for market share.”
= = = = = = = = = = = = = = = = = = = = = = =
AVID BIOSERVICES, Inc. (Peregrine's Mfg. Subsidiary): http://www.avidbio.com
7-14-17: PPHM's Revs & Burns By Qtr Table, FY'07/Q1 thru FY'17/Q4 (q/e 4-30-17): http://tinyurl.com/yb4wulvu (since 5-2006: Avid=$231.2mm, Total=$257.8mm, incl.Govt)
......Avid FY18 (fye 4-30-18) revs guidance: $50-55mm; committed backlog=$58mm. Recently Leased +42,000sf in same bldg. as MYFORD for future expansion."
7-14-17: Avid Scientists develop “Antibody Discovery & Characterization Platform” http://tinyurl.com/ycr3erft
...S.King: “through which we can generate antibodies against virtually any target. These capabilities are state-of-the-art and meant for rapid screening for high affinity antibodies as drug candidates.”
5-2017: Avid II (Myford) adds 2 MilliporeSigma Mobius 2,000L single-use bioreactors; total mfg. capacity now ">11,000L". http://tinyurl.com/ky7bmu4
5-10-17: Halozyme comments on Avid II(Myford) expansion in their 3-31-17/10Q pub. 5-9-17: http://tinyurl.com/mrl34uk
..."validation of the new facility is scheduled to end in Q2/2017… Once this new facility is approved, it will become the primary source for Roche of bulk rHuPH20.”
Next post updated w/Tappan's new 13G: adds +1,384,380=>now 2,298,684=5.1%
Known Upcoming Events, Large-Shareholders(31%), RONIN-PPHM HISTORY, updated 7-20-17 with a Ronin/SW “Letter to Employees of Peregrine”
KNOWN UPCOMING:
Jul25: Neo-Synth’s "Precision: Lung Cancer - World R&D Summit", Boston http://tinyurl.com/ydcxlkja
...12:00pm: Bruce Freimark (Res.Dir/PreClin-Oncol), “Overriding PS-Mediated Tumor Immune Suppression to Enhance Immune Checkpoint Therapies”
Jul27: Final Settlement Hearing for 2013 Shareholder Derivative CA Lawsuit vs. BOD http://tinyurl.com/y982h3rt
Aug15-16: CBI’s MES 2017 (Mfg. Execution Systems), Orlando http://tinyurl.com/ya4twmbj
...Aug16/8:45am: Mehron Mirian (SeniorMgr./QA Validation), "MES AUDIT DEEP DIVE Computerized System Audit"
Aug21-25/Avid Booth #403: CHI's 9th Annual BioProcessing Summit, Boston http://www.bioprocessingsummit.com
~Sep7: FY'18Q1 (qe 7-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
Sep25-28/Avid Booth #918: Informa’s BPI’17: BioProcess Intl. Conf. & Exhibition, Boston https://lifesciences.knect365.com/bioprocessinternational
Oct2/NCI Scientist Gregoire Altan-Bonnet(MSKCC ties), AACR’s Tumor Immunotherapy Conf., Boston http://tinyurl.com/y74v76go
...“Long-Lived Disruption of Inflammation Stems from the Catch-and-Release of Cytokines Mediated by Surface Phosphatidylserine in Tumors”
~Oct12: Peregrine's Annual Shareholder’s Meeting (2016 attendee reports: http://tinyurl.com/jx7ouay )
Dec11-15/Avid Booth #311: KNect365’s Antibody Eng. & Therapeutics Conf., SanDiego https://lifesciences.knect365.com/antibody-engineering-therapeutics
~Dec11: FY'18Q2 (qe 10-31-17) Financials & Conf. Call - http://ir.peregrineinc.com/events.cfm
= = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
7-24-17: Large Ownership Summary(31%), RONIN Letters/PPHM Comments
Large Ownership now ~13.9mm shares, 31.0% of 45mm O/S. (Ronin+SW/Stafford+White, Eastern Cap./K.Dart, Institutions)
#1: 10-30-15: Kenneth Dart (Eastern Capital) acquires 9.6% stake (4,300,992sh.) in PPHM http://tinyurl.com/y95yskck
...3,777,183 COMMON – 8.4% of 45,069,188 common O/S at 7-10-17 (total beneficial=4,300,992 if Pref. conv. x1.19 to Common, 9.6%)
...440,000 PREFERRED – 26.7% of 1,647,760 preferred O/S at 1-31-17
#2: 7-14-17/13D: Group Ronin Trading/SWInvest (John Stafford III+Stephen White) acquires 8.8% stake (3,952,446sh.) in PPHM http://tinyurl.com/y7ezqvm9
...3,801,139 COMMON – 8.4% of 45,069,188 common O/S at 7-10-17 (total beneficial=3,952,446 if Pref. conv. x1.19 to Common, 8.8%)
...127,099 PREFERRED – 7.7% of 1,647,760 preferred O/S at 1-31-17
NOTE: ALL historical common #’s adjusted for the 1:7 R/S eff. 7-10-17.
RONIN/SW 13D SUMMARY:
13D TransDates COMMON-CHG PREF-CHG ENDING-COMMON ENDING-PREF.
3-2-17 1/20/17-3/1/17 +2,947,425 +51,364 2,947,425 51,364 http://tinyurl.com/jr42u23
3-10-17 3/2/17-3/9/17 +433,509 +25,661 3,380,934 77,025 http://tinyurl.com/ydxra96u
4-17-17 3/28/17-4/10/17 0 +23,334 3,380,934 100,359 http://tinyurl.com/lanjddc
5-19-17 5/1/17-5/17/17 0 +23,140 3,380,934 123,499 http://tinyurl.com/mgnn92x
6-20-17 3/10/17-6/16/17 +378,170 0 3,759,105 123,499 http://tinyurl.com/y76q5rqu
6-29-17 6/21/17 +7,143 0 3,766,248 123,499 http://tinyurl.com/y9sp8bfv
7-14-17 6/29/17-7/7/17 +34,891 +3,600 3,801,139 127,099 http://tinyurl.com/ybra4s69
SPLITOUT 13D GROUP into Ronin(John Stafford III) and SW-Partners(Stephen White):
Ronin Trading (Stafford) 3,173,391 115,299
SW-Partners (White) 627,748 11,800
See 13D Details Below.
- - - - - - - - - - - - - - -
Plus, INSTITUTIONS a/o 3-31-17: 5,690,888sh. = 12.6% (of $5mm) http://www.nasdaq.com/symbol/pphm/institutional-holdings
TOP5:
Kennedy Capital Mgt. 1,247,224 +164,952
Tappan Street Partners 914,304 +914,304
Vanguard Group 882,964 +267,438
Blackrock (Larry Fink, CEO) 855,455 +177,856
Renaissance Technologies 439,673 +6,259
Corp, all existing ATM’s are now exhausted, and if any new ones are opened (and reported via Form 424B5), they go against the $67mm remaining on the original $150mm shelf filed via this 4-23-14 S-3:
https://www.sec.gov/Archives/edgar/data/704562/000101968714004801/peregrine_s3-122314.htm
The last ATM agreement’s (8-7-15/Nobel $20mm) 424B5 said this:
“This prospectus is part of a registration statement on Form S-3 that we filed with the SEC utilizing a “shelf” registration process. Under the shelf registration process, we may offer & sell either individually or in combination with other securities any of the securities described in this prospectus from time to time in one or more offerings at prices and on terms to be determined at or prior to the applicable offering. The aggregate initial offering price of all securities sold under this prospectus will not exceed $150,000,000.”
http://tinyurl.com/oc53ugn
= = = = = = = = = = = = = =
7-18-17: All existing ATM’s are fully executed a/o 7-14-17/10K. There can be no further ATM sales until PPHM enters another agreement with a firm like Noble or MLV and files a Form 424B5, like they’ve always done in the past.
See: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=133107514
Tradero, always an extra 4th month before Q4/fye in July, so then only 2mos to Q1 in September. Last yr's Q1 was Thur. 9-8-16; that's why I estimated Thur. 9-7-17. They may chg. it by a day or 2.
All existing ATM’s are fully executed a/o 7-14-17/10K. There can be no further ATM sales until PPHM enters another agreement with a firm like Noble or MLV and files a Form 424B5, like they’ve always done in the past. See examples below.
...If I'm wrong about this, let me know and I will correct & repost.
LOOK HERE and see that ALL existing ATM Agreements now have ZERO Balances:
A-T-M (At-The-Market) Sales 3/2009 – 7/14/17 ($272,500,000gr./34,869,747sh=$7.81/sh): http://tinyurl.com/yagmu2on
Examples of the Last 3 ATM Agreements and Filed 424B5’s:
…6-13-14: New ATM Agreement (up to $25mm) with MLV filed - 424B5: http://tinyurl.com/ycxje6pj
…8-7-15: New ATM Agreement (up to $20mm) with NOBLE filed - 424B5: http://tinyurl.com/q9zvw6n
…8-7-15: New ATM Agreement (up to $30mm) with MLV filed - 424B5: http://tinyurl.com/oc53ugn
Latest 10K: A/o Fye 4-30-17 iss. 7-14-17 http://tinyurl.com/ycxu4l5n
7-14-17: Ronin/SWIM (stake=8.8%), Letters to SH’s, PPHM Comments
New 13D – see below for Ronin Letters & PPHM Responses..
7-14-17/13D: Group Ronin/SWPartners adds 34,891/Common + 3,600/Pref. Jun29-Jul7
...brings total ownership of the Group to:
3,801,139 COMMON - 8.4% of 45,069,188 common O/S at 7-10-17
127,099 PREFERRED – 7.7% of 1,647,760 preferred O/S at 1-31-17
...Total “beneficial”=3,952,446 (3,310,651/ronin + 641,795/sw) if Preferred conv. to Common (x1.19), 8.8% of 45,069,188 O/S.
NOTE: ALL historical Common #’s adjusted for the 1:7 R/S eff. 7-10-17.
13D TransDates COMMON-CHG PREF-CHG ENDING-COMMON ENDING-PREF.
3-2-17 1/20/17-3/1/17 +2,947,425 +51,364 2,947,425 51,364 http://tinyurl.com/jr42u23
3-10-17 3/2/17-3/9/17 +433,509 +25,661 3,380,934 77,025 http://tinyurl.com/ydxra96u
4-17-17 3/28/17-4/10/17 0 +23,334 3,380,934 100,359 http://tinyurl.com/lanjddc
5-19-17 5/1/17-5/17/17 0 +23,140 3,380,934 123,499 http://tinyurl.com/mgnn92x
6-20-17 3/10/17-6/16/17 +378,170 0 3,759,105 123,499 http://tinyurl.com/y76q5rqu
6-29-17 6/21/17 +7,143 0 3,766,248 123,499 http://tinyurl.com/y9sp8bfv
7-14-17 6/29/17-7/7/17 +34,891 +3,600 3,801,139 127,099 http://tinyurl.com/ybra4s69
SPLITOUT 13D GROUP into Ronin(John Stafford III) and SW-Partners(Stephen White):
Ronin Trading (Stafford) 3,173,391 115,299
SW-Partners (White) 627,748 11,800
See 13D Details Below.
TOP5:
Kennedy Capital Mgt. 1,247,224 +164,952
Tappan Street Partners 914,304 +914,304
Vanguard Group 882,964 +267,438
Blackrock (Larry Fink, CEO) 855,455 +177,856
Renaissance Technologies 439,673 +6,259